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The IL-17 family of cytokines is structurally distinct from other cytokine subclasses, and 
is composed of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25) and IL-17F. Among the IL-17 
family, IL-17A and IL-17F share the most homology at the amino acid level. Both of these 
cytokines activate qualitatively similar downstream signals via binding with the IL-17RA:RC 
receptor complex but with different binding affinities. Consequently, similar disease susceptibility 
is observed in Il17a-/- and Il17f-/- mice in some animal models, for example autoimmune 
glomerulonephritis (AGN). However, IL-17A and IL-17F sometimes exhibit distinct biological 
activities in other settings, both infectious and autoimmune. This dichotomy is particularly 
illustrated in oropharyngeal candidiasis (OPC) and dextran sulfate sodium (DSS)-induced colitis. 
The mechanisms behind the surprisingly different in vivo functions of IL-17A and IL-17F remain 
largely underexplored. In order to further understand the function of IL-17F and potentially 
explore the mechanism by which IL-17A and IL-17F exhibit distinct roles in vivo, I took advantage 
of a naturally occurring human mutation that causes reduced binding affinity of IL-17F to the IL-
17RA/RC receptor (IL-17F.S65L). In this dissertation, I describe the development of an IL-
17F.S65L mouse strain (Il17fS65L/S65L), which I used to decipher the function of IL-17F in the 
settings of OPC, DSS colitis, and AGN.  In Chapter 3, I show that Il17fS65L/S65L mice have increased 
susceptibility to OPC, which is similar to Il17a-/- but not Il17f-/- mice. In Chapter 4, I present data 
showing that Il17fS65L/S65L mice and Il17a-/- mice also have a similarly increased susceptibility to 
DSS colitis that contrasts with Il17f-/- mice. Surprisingly, however, the murine IL-17F.S65L 
 v 
mutation does not impact the development of AGN, despite the fact that Il17a-/- and Il17f-/- mice 
were both fully resistant to kidney damage in this disease model. For each model system, I present 
the outcomes and our current understanding of the underlying mechanisms. Overall, this 
dissertation research has helped to delineate the different in vivo activities of IL-17A and IL-17F 
and could potentially be beneficial for the development of IL-17F targeted therapy.  
  
 vi 
Table of Contents 
List of Abbreviations ................................................................................................................. xiii 
Acknowledgements .................................................................................................................. xviii 
1.0 Introduction ............................................................................................................................. 1 
1.1 Cytokines in the immune response ............................................................................... 1 
1.2 Interleukin (IL)-17 family cytokines and their receptors ........................................... 2 
1.3 IL-17A and IL-17F signal transduction ....................................................................... 5 
1.4 Biological activities of IL-17A and IL-17F ................................................................. 11 
1.4.1 The role of IL-17 signaling in oropharyngeal candidiasis (OPC) ..................14 
1.4.1.1 Function of IL-17A; evidence from clinical studies ............................ 14 
1.4.1.2 Lesson from an “experiment of nature”; IL-17F deficiency in CMCD 
patients ................................................................................................................ 15 
1.4.1.3 Animal research predicts clinical outcomes; Understanding IL-17A 
and IL-17F by murine OPC .............................................................................. 16 
1.4.1.4 C. albicans recognition and the induction requirement of type 17 
immunity ............................................................................................................. 16 
1.4.1.5 Oral epithelium: One target site of IL-17 signaling ........................... 21 
1.4.1.6 Mechanism of IL-17-mediated fungal clearance ................................ 22 
1.4.2 The role of IL-17 signaling in autoimmunity ...................................................23 
1.4.2.1 IL-17A and IL-17F in inflammatory bowel disease (IBD) ................. 23 
1.4.2.2 The role of IL-17 signaling in autoimmune glomerulonephritis (AGN)
 ............................................................................................................................. 27 
 vii 
1.5 Summary ....................................................................................................................... 30 
2.0 Methods and Materials ......................................................................................................... 32 
2.1 Materials ........................................................................................................................ 32 
2.1.1 Mice .....................................................................................................................32 
2.1.2 Cell and cytokines ..............................................................................................32 
2.1.3 Antibodies ...........................................................................................................33 
2.1.4 qRT-PCR primers ..............................................................................................34 
2.2 Methods ......................................................................................................................... 35 
2.2.1 Generation of Il17fS65L/S65L knock-in mice ........................................................35 
2.2.2 Model of OPC .....................................................................................................38 
2.2.3 Leukocytes isolation and enrichment from tongue tissues .............................39 
2.2.4 Flow cytometry ...................................................................................................39 
2.2.5 RNA extraction, Quantitative PCR and RNAseq ...........................................39 
2.2.6 IL-17RA deficient cell line development ..........................................................40 
2.2.7 IL-17F and IL-17F.S65L activation .................................................................41 
2.2.8 Th17 differentiation and ELISA .......................................................................41 
2.2.9 Histology and Immunohistochemistry .............................................................42 
2.2.10 Model of DSS colitis and FITC-Dextran Administration .............................42 
2.2.11 Colonic lamina propria cell isolation .............................................................43 
2.2.12 Fecal bacterium isolation and enteric C. XIVa determination ....................43 
2.2.13 Model of anti-GBM nephritis ..........................................................................44 
3.0 An Il-17F.S65L knockin mouse reveals similarities and differences in IL-17F 
function in oral candidiasis: A new tool to understand IL-17F ......................................... 45 
 viii 
3.1 Background ................................................................................................................... 46 
3.2 Results ............................................................................................................................ 47 
3.2.1 Murine IL-17F S65L is a loss-of-function mutation .......................................47 
3.2.2 Il17fS65L/S65L mice are modestly susceptible to OPC ........................................50 
3.2.3 Il17fS65L/S65L mice show mildly impaired neutrophil recruitment during OPC
 .......................................................................................................................................54 
3.2.4 Increased OPC in Il17fS65L/S65L mice is not due to impaired IL-17A .............57 
3.2.5 IL-17F is produced dominantly by γδ T cells ..................................................59 
3.2.6 The intestinal microbiome is required for fungal clearance during OPC ....61 
3.2.7 c-Fos is not required for protection against C. albicans oral infection .........63 
3.3 Discussion ...................................................................................................................... 67 
4.0 Divergent functions of IL-17-family cytokines in autoimmune disease:  Lessons 
from a naturally-occurring human mutation in IL-17F ..................................................... 74 
4.1 Background ................................................................................................................... 74 
4.2 Results ............................................................................................................................ 76 
4.2.1 IL-17A and IL-17F play opposing roles in DSS colitis ...................................76 
4.2.2 Il17fS65L/S65L mice showed an increased susceptibility in DSS colitis .............79 
4.2.3 Decreased colonization of intestinal Clostridium cluster XIVa in Il17fS65L/S65L 
mice ...............................................................................................................................81 
4.2.4 IL-17F.S65L regulates colonic Treg cell levels ................................................83 
4.2.5 Defining signaling activities of IL-17A and IL-17F in DSS colitis .................85 
4.2.6 IL-17F.S65L does not affect the development of AGN ...................................91 
4.3 Discussion ...................................................................................................................... 92 
 ix 
5.0 Conclusion and Future directions ....................................................................................... 99 
5.1 Summary ....................................................................................................................... 99 
5.2 Unifying discussion, outstanding questions and future directions ......................... 100 
5.3 Conclusion ................................................................................................................... 107 
Bibliography .............................................................................................................................. 109 
 x 
List of Tables 
Table 1.4.1 IL-17 target therapies in psoriasis ......................................................................... 13 
Table 1.4.2 The biological activities of IL-17A and IL-17F in infectious and inflammatory 
diseases ............................................................................................................................. 13 
Table 1.4.3 Functions of IL-17A in mouse models of IBD ...................................................... 27 
Table 1.4.4 Animal models of nephritis (adapted from (H. C. Yang, Zuo, & Fogo, 2010)) . 30 
Table 2.1.1 List of antibodies ..................................................................................................... 33 
Table 2.1.2 List of bacterium qPCR primers ........................................................................... 34 
Table 2.1.3 List of commercial qRT-PCR primers .................................................................. 34 
Table 2.2.1 Off-target screening of Il17fS65L mutant mice ....................................................... 37 
Table 4.2.1 Genes upregulated by IL-17F in WT fibroblasts ................................................. 89 






List of Figures 
Figure 1.1: Structures of IL-17A and IL-17F ............................................................................. 3 
Figure 1.2: IL-17 Cytokine and Receptor Family ...................................................................... 5 
Figure 1.3 Interleukin (IL)-17RA/RC signaling pathways ..................................................... 10 
Figure 1.4 Activation of Type 17 immune response during OPC........................................... 20 
Figure 1.5 Structure of the oral mucosa ................................................................................... 22 
Figure 3.1 Murine IL-17F.S65L is a loss-of-function mutation .............................................. 49 
Figure 3.2. Glycosylation site prediction in murine IL-17F .................................................... 50 
Figure 3.3 Il17fS65L/S65L mice are modestly susceptible to OPC ............................................... 53 
Figure 3.4 Genomic DNA sequencing of IL-17F.S65L mutation............................................ 54 
Figure 3.5 IL-17F.S65L mice exhibit impaired neutrophil recruitment during OPC.......... 56 
Figure 3.6 The IL-17F.S65L mutation does not influence IL-17A production from T cells 58 
Figure 3.7 IL-17A does not compensate for IL-17F signaling in Il17fS65L/S65L mice during OPC
........................................................................................................................................... 59 
Figure 3.8 IL-17F is dominantly produced by oral γδ-T cells during OPC .......................... 61 
Figure 3.9 Commensal microbiome is essential for antifungal immunity during OPC ....... 63 
Figure 3.10 c-Fos expression at oral epithelium during OPC ................................................. 64 
Figure 3.11 c-Fos is not required for antifungal immunity during OPC ............................... 66 
Figure 4.1 Inhibition of IL-17A and IL-17F showed opposite phenotypes in DSS-induced 
colitis................................................................................................................................. 78 
Figure 4.2 Il17fS65L/S65L mice are susceptible to DSS-induced colitis ...................................... 80 
Figure 4.3 The commensl C. XIVa population is reduced in Il17fS65L/S65L mice .................... 82 
 xii 
Figure 4.4 IL-17F.S65L mutation is associated with a reduced Foxp3+ Treg cell poplulation 
in colon ............................................................................................................................. 84 
Figure 4.5 IL-17RA is required for IL-17F signaling .............................................................. 87 
Figure 4.6 IL-17F.S65L mutation exhibits a distinct phenotype from loss of either IL-17A or 
IL-17F............................................................................................................................... 92 
Figure 4.7 Speculative IL-17RA/RC and IL-17RC axis in DSS colitis model ....................... 98 
Figure 5.1 Speculative IL-17RA/RC and IL-17RC axis in OPC model ............................... 106 
Figure 5.2 Speculative IL-17RA/RC and IL-17RC axis in AGN model .............................. 107 
 
 xiii 
List of Abbreviations 
α-MEM – Minimum Essential Medium α 
AGN – Autoimmune glomerulonephritis 
AIDS – Acquired immunodeficiency syndrome 
AIRE – Autoimmune regulator 
AP-1 – Activator protein 1 
APC – Antigen-presenting cell 
APECED – Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy 
AMP – Antimicrobial peptide 
ANCA – Antineutrophil cytoplasmic antibodies 
ASF/SF2 – Alternative splicing factor 1 (ASF1), pre-mRNA-splicing factor SF2 (SF2) 
BEL – Basal epithelial layer 
BUN – Blood urea nitrogen 
CARD9 – Caspase Recruitment Domain Family Member 9 
CBAD – C/EBPβ activation domain 
CCL – C-C motif ligand 
CD – Crohn's disease 
C/EBP – CCAAT-enhancer-binding proteins 
CFU – Colony-forming unit 
CIK – Connection to IκB kinase and Stress-activated protein kinases 
CKD – chronic kidney damage 
CMCD – Chronic mucocutaneous candidiasis Disease 
 xiv 
CRISPR – Clustered Regularly Interspaced Short Palindromic Repeats 
CTLA-8 – Cytotoxic T-lymphocyte–associated antigen 
CXCL – C-X-C motif ligand 
C. XIVa – Clostridium cluster XIVa 
DMEM – Gibco Dulbecco's Modified Eagle Medium 
DSS – Dextran sulfate sodium 
DTT – Dithiothreitol 
EAE – Experimental autoimmune encephalomyelitis 
E. coli – Escherichia coli 
EDTA – Ethylenediaminetetraacetic acid 
EGF – Epidermal growth factor 
ELISA – Enzyme-linked immunosorbent assay 
ERK – Extracellular-signal-regulated kinase 
FBS – Fetal bovine serum 
FGF2 – Fibroblast Growth Factor 2 
FITC – Fluorescein isothiocyanate 
FN III – Fibronectin type III 
GBM – Glomerular basement membrane 
G-CSF – Granulocyte colony-stimulating factor 
GM-CSF – Granulocyte-macrophage colony-stimulating factor  
GSA – Gene Specific Analysis 
GWAS – Genome-wide association study 
HBSS – Hanks' Balanced Salt Solution 
 xv 
HIV – Human immunodeficiency virus 
HDR – Homology directed repair 
HuR – Human antigen R 
IACCUC – Institutional animal care and use committee 
IBD – Inflammatory bowel disease 
IFN – Interferon 
IL – Interleukin 
IgA – Immunoglobulin A 
ILC – Innate lymphoid cells 
IKK – inhibitor of NF-κB kinase 
K4 – Keratin 4  
K5 – Keratin 5 
K13 – Keratin 13 
K14 – Keratin 14 
K19 – Keratin 19 
LT – Lymphotoxin 
MAPK – Mitogen-activated protein kinase 
MCPIP – MCP-induced protein 
MMP – Matrix metalloproteinase 
mRNA – Messenger ribonucleic acid 
MRSA – Methicillin-resistant staphylococcus aureus 
MYD88 – Myeloid differentiation primary response 88 
NIAID – National institute of allergy and infectious diseases 
 xvi 
NIH – National Institutes of health 
NIK – NF-κB-inducing kinase 
NF-κB – Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF – Nerve growth factor 
Ni-NTA- Nickel charged nitrilotriacetic acid 
NK – Natural killer cells 
OD – Optical density 
OPC – Oropharyngeal candidiasis 
PAM – Protospacer adjacent motif 
PAMP – Pathogen associated molecular patterns 
PBS – Phosphate-buffered saline 
PCR – Polymerase chain reaction 
PEN-STREP – Penicillin-Streptomycin 
RBP – RNA binding protein 
RORγT – RAR-related orphan receptor gamma 
S. aureus – Staphylococcus aureus 
SD – Standard Deviation 
SDS-PAGE – Sodium dodecyl sulfate - Polyacrylamide gel electrophoresis 
SEFIR – Similar expression of fibroblast growth factor and IL-17R 
SEFEX – SEFIR-Extension 
SEL – Suprabasal epithelial layer 
SEM – Standard error of the mean 
sgRNA – Single guide RNA 
 xvii 
SPF – Specific pathogen free 
STAT3 – Signal transducer and activator of transcription 3 
TAK – β-activated kinase 
TCR – T-cell receptor 
Teff – T effector cells 
TGFβ – Transforming growth factor beta 
Th17 – T helper 17 
TILL – TIR-like loop 
TIR – Toll-like receptor/Interleukin (IL)-1 receptor 
TLR – Toll like receptor 
TNBS – Trinitrobenzenesulfonic acid 
TNFα – Tumor necrosis factor alpha 
TRAF – TNF Receptor Associated Factor 
Treg – T regulatory cells 
TRIF – TIR-domain-containing adapter-inducing interferon-β 
UC – Ulcerative colitis 
UCSC – University of California Santa Cruz 
UTR – Untranslated region 
WT – Wild type 
YPD – Yeast extract peptone dextrose 
 xviii 
Acknowledgements 
The journey of Ph.D. training is a memorable life experience but also full of challenges. I 
would like to appreciate all the people who help me to conquer these challenges and provide a 
great deal of support for completing doctoral studies. First of all, I would like to give my sincere 
gratitude to my mentor, Dr. Sarah Gaffen for all her time and efforts to lead me through my training 
over the years. She is such a great mentor that does not only teach me how to become a good 
scientist but also cares my mental health and personal safety. All of these show her great love to 
her students. 
I am deeply grateful to my thesis committee members, Drs Biswas, Kane, St. Leger, and 
Sfeir. This work would not be possible to accomplished without their invaluable advice and 
continuous support. I would particularly thank to all the past and present members of Gaffen lab, 
Yang, Rami, Felix, Tiffany, Bianca, Katie, Akash, Giraldina, Jamie, Agustin for all the scientific 
advice and great time we spend together. It’s my pleasure to work with all of you and build up 
friendships throughout the years. I would give my special thanks to Katie for proofreading this 
dissertation. I would also like to thank Drs. Biswas, McGeachy and their lab members for great 
collaboration. I am grateful to Drs. Hand and Kaplan for providing their precious mice and 
facilities.   
I would like to thank Dr. Haidong Dong in Mayo clinic and Dr. Li Li in BD Biosciences 
for leading to the field of immunology. I am deeply grateful to my lovely mother, Juhong, and my 
dear uncle, Quanhong, for their everlasting support, both mentally and physically. I would like to 
give my deepest appreciation and love to my wife Evelyn. Thank you for your love and comfort, 
which make me complete and strong to face all the challenges throughout my Ph.D. training. It is 
 xix 
my great honor to be with you throughout this journey. I am eternally grateful to the Mighty God. 
It is your will to bring me into Pittsburgh and the journey of the Ph.D. studies. Thank you for being 
with me and give me your strength and wisdom for my accomplishment. All glory be to God.  
 1 
1.0 Introduction 
1.1 Cytokines in the immune response 
The immune system is a complex network through which the human body defends against 
infections. Impressively, the immune system is able to specifically recognize and eliminate 
pathogenic invaders yet keep responses benign to self or nonharmful components. Thus, the 
immune system is required to be tightly regulated, and communication among immune cells is 
critical to maintain appropriate regulation in the system.   
Cytokines are signaling mediators that immune cells use for communication. They 
comprise proteins that are secreted by hematopoietic cells and many other types of cells in response 
to external stimuli. Cytokines regulate their target cells by binding to cognate cell surface receptors, 
which results in effector functions such as hematopoiesis, differentiation, migration, proliferation, 
survival, and apoptosis. The studies of cytokines started as early as the 1950s [1], but the term 
“cytokine” was first proposed by Stanley Cohen in 1974 [2]. Today, almost 200 cytokines or genes 
coding for cytokine-like activities have been described [3]. Cytokines are usually classified 
according to the type of receptors that they bind on target cells. Cytokine families include those 
that signal through (i) type I and type II hematopoietic cytokines, such as the IL-2, IL-6, IL-10, 
and type I, II and III IFN families; (ii) immunoglobulin (Ig) receptors, including the IL-1 family; 
(iii) TNF receptor family receptors; and (iv) chemokine G-protein coupled receptors. Additional 
cytokine families are characterized by their unique structures and functions, such as (i) the IL-17 
family; (ii) growth factors and glycoprotein hormones with immunological functions, including 
insulin, TGF superfamily, and EGF family; and (iii) morphogen factors with immunological 
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function, including the Notch and Wnt systems [4]. The IL-17 family cytokines share unique 
structure features that distinguish them from the above-mentioned cytokine subclasses. In this 
dissertation, I will focus on the biological functions of IL-17A and IL-17F, two members of the 
IL-17 family of cytokines.  
1.2 Interleukin (IL)-17 family cytokines and their receptors 
IL-17A, originally named CTLA-8, is the founding member of the IL-17 family. By 
comparing sequence homology with IL-17A, five additional members were identified and named 
IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and IL-17F [5-11]. Among these 
cytokines, IL-17A and IL-17F share the most homology at the amino acid sequence level (56%) 
[6]. Protein structural analysis further elucidated the similarity between IL-17A and IL-17F in 
terms of tertiary structures. Superimposing the backbone Cα
 atoms of IL-17A to those of IL-17F 
revealed a comparable conformational arrangement (Figure 1.1) [12]. Studies of crystallographic 
structures of IL-17A and IL-17F showed that these two cytokines adopt a cysteine knot fold, which 
is commonly found in neurotropin proteins such as nerve growth factor (NGF) but not in other 
cytokine families [6, 13]. The cysteine knot fold is characterized by two pairs of anti-parallel β-
strands bundled through two disulfide bonds and an extra pair of serine residues [12]. The β-strands, 
disulfide bridges and serine residues are conserved across all the six members of the IL-17 family. 





Figure 1.1: Structures of IL-17A and IL-17F 
Figure is adopted from [12]. (A) Structures of IL-17A and IL-17F are superimposed as indicated. 145 Cα atoms were 
involved in the superimposition. Disulfide binds in IL-17F are indicated as yellow spheres. Figures were generated by 
the program PyMOL. (B) Topological diagram of IL-17A and IL-17F with the cysteine knot fold features. Conserved 
cysteines and serines are indicated by yellow circles. The two presented disulfide bonds are showed by red lines, and 





It is not surprising that, given the unique structure of IL-17 family ligands, these cytokines 
signal through a receptor family that is also distinct from other known cytokine receptors. The IL-
17R family contains 5 members, IL-17RA-RE [14, 15]. All of these members share a common 
intracellular motif known as a SEFIR (similar expression of fibroblast growth factor and IL-17R) 
and two extracellular fibronectin III-like (FnIII) domains, referred to as D1and D2) [16]. The 
intracellular SEFIR domain is structurally similar to the TIR domain found in the TLR/IL-1R 
family. This domain is critical for activating downstream signals and will be further discussed 
below [17]. FnIII domains are responsible for cytokine binding [12, 18]. A crystallographic 
structure of IL-17F in complex with IL-17RA revealed that a small loop of edge strands from the 
FnIII domains was inserted into a groove formed at the dimeric interface of IL-17F. This 
interaction therefore created a buried contact area containing multiple hydrogen bonds as well as 
salt bridges, which stabilized binding between the cytokine and its receptor. Crystallographic 
analysis of IL-17A in complex with IL-17RA revealed that IL-17A adopts a similar receptor-ligand 
interaction to IL-17F [19]. However, direct binding assays showed relatively low binding affinities 
of IL-17RA alone to IL-17A or IL-17F [18, 20]. Considering the low concentrations at which 
cytokines achieve their biological activities, it became clear that an extra component was needed 
to facilitate the interaction between the IL-17 cytokines and their receptors.  
Indeed, the IL-17 cytokines were found to signal through heterodimeric receptor 
complexes. In the IL-17 family, most heterodimeric receptor complexes are composed of a 
common IL-17RA chain and a second chain that specifically binds to different members of the IL-
17 family (Figure 1.2). IL-17A and IL-17F share IL-17RC as their second subunit [21]. Recent 
studies in 2019 suggested that IL-17A may also use IL-17RA:IL-17RD receptor complex for 
signaling and that IL-17F may have an ability to bind to an IL-17RC homodimers [22-24], though 
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neither of these studies has yet been replicated. Hence, our understanding of ligand-receptor 
binding activities of IL-17A and IL-17F is still developing. The members of IL-17 family and their 




Figure 1.2: IL-17 Cytokine and Receptor Family 
Members of IL-17 cytokines of family and their receptors are indicated. Each member of IL-17 receptor family is 
indicated with different colors. Many IL-17 family cytokines interact with a heterodimeric receptor composed of IL-
17RA and a second chain belonging to the IL-17 receptor family, with an exception of IL-17F that has been recently 
showed to interact with IL-17RC homodimeric complex. IL-17 receptors share the SEFIR domain as a common 
cytoplasmic motif. Unique SEFEX and CBAD domains can also be found in cytoplasmic tail of IL-17RA.  
1.3 IL-17A and IL-17F signal transduction 
The highly conserved structure of IL-17A and IL-17F and their common receptor 
complexes causes them to trigger qualitatively similar signaling pathways. IL-17A promotes non-
hematopoietic cells to express a characteristic gene signature, including a variety of cytokines (IL-
 6 
6, GM-CSF, G-CSF), chemokines (CXCL1, CXCL2, CXCL8, CCL2, CCL7, CCL20), matrix 
metalloproteinases (MMP1, 2, 3, 9, 13), transcriptional and posttranscriptional regulators (C/EBPs, 
IκBξ, Regnase-1, Arid5a), and antimicrobial peptides (β-defensins, S100A proteins, lipocalin 2) 
[25-28]. IL-17F induces a similar, yet not entirely overlapping, gene profile [28-32]. Lack of either 
IL-17RA or IL-17RC leads to a complete loss of responsiveness upon the activation of IL-17A or 
IL-17F [21]. 
 Dimerization of the cytokines is required for the binding of IL-17A or IL-17F to the IL-
17RA:RC receptor complex. IL-17A and IL-17F can be produced as homodimers but also exist as 
an IL-17A/F heterodimer [33]. All of these dimers (IL-17A:A, F:F, A:F) can bind and signal 
through the IL-17RA:RC receptor complex but with different binding affinities and signaling 
strengths, with AA>AF>FF [34, 35].  
Not surprisingly, the intracellular domains of IL-17RA and IL-17RC are critical for IL-17 
signal transduction [36-38]. As noted above, the SEFIR is a conserved intracellular domain found 
in all members of the IL-17R family including IL-17RA and IL-17RC [17]. Although the structure 
of the SEFIR is similar to that of a TIR domain, IL-17RA signaling does not require canonical TIR 
adaptors such as MYD88 and TRIF [38]. Rather, Act1, also known as connection to IκB kinase 
and Stress-activated protein kinases (CIKS), is the essential adaptor for SEFIR domain in all 
known IL-17-dependent pathways [25, 39]. Act1 also contains a SEFIR motif, which mediates 
homotypic interactions with the SEFIR domains in IL-17RA and IL-17RC [40]. Upon the binding 
of IL-17RA to its ligand, a conformational change occurs in the N-terminal region of the IL-17A 
dimer. Specifically, β-strands 1 and 2 of IL-17A (figure 1.1) bend toward IL-17RA, and the loops 
connecting β-strands 1-2 and 3-4 move away from the FnIII domain of the receptor. The 
conformational change leads to steric clashes that prevent the binding of another IL-17RA to the 
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IL-17A dimer and favor the selective interaction with IL-17RC to form the heterodimeric signaling 
complex. The IL-17RA/RC receptor complex provides a platform for the homotypic interactions 
with Act1. Act1 is thus recruited to the signaling complex for the downstream signaling [16, 18, 
19, 41].  
However, the conserved SEFIR domain alone is not sufficient to drive IL-17 signal 
transduction. Detailed mutagenesis studies of IL-17RA showed that deletion of ~100 residues after 
the SEFIR domain in IL-17RA significantly dampens IL-17 signaling activity [28, 38]. This 
extension of the SEFIR in IL-17RA was first termed TILL (TIR-like loop) because of its similarity 
to the BB-loop in TIR domains, and later renamed “SEFIR-Extension” (SEFEX) (shown in Figure 
1.2). The SEFEX and the SEFIR together make a composite domain that is important for activation 
of TNF Receptor Associated Factor 6 (TRAF6), another critical component in IL-17 signaling 
pathway [28]. Surprisingly, the SEFEX is not conserved among IL-17 family receptors. However, 
deletion studies suggest that a short extension of the SEFIR motif in IL-17RC is similarly required 
for receptor functionality [36, 42]. Therefore, the SEFIR and SEFEX together comprise an 
essential composite domain needed for IL-17 signal transduction.  
The IL-17 signaling pathway is initiated by an interaction between Act1 and TRAF6. Act1 
is a lysine-63 (K63) E3 ubiquitin ligase that ubiquitinates TRAF6 upon IL-17 stimulation of the 
receptor [43, 44]. The ubiquitination of TRAF6 provides a scaffold for the recruitment of the 
transforming growth factor β-activated kinase (TAK)1 and the inhibitor of NF-κB kinase (IKK) 
complex, which further activates the canonical nuclear factor κB (NF-κB) transcription factor [45-
47]. However, the non-canonical NF-κB pathway, characterized by NF-κB-inducing kinase (NIK),  
was not found to be activated by IL-17A or IL-17F [15]. IL-17 signaling also activates mitogen-
activated protein kinase (MAPK) pathways, which include extracellular signal-regulated kinase 
 8 
(ERK), p38 and JUN N-terminal kinase (JNK) [48-51]. All these pathways work together to 
transcriptionally activate the target genes downstream of IL-17A and IL-17F.  
In addition, post-transcriptional gene regulation plays an important role in IL-17 signaling, 
which is mainly established by controlling mRNA stability. IL-17A and IL-17F only modestly 
activate transcription factors such as NF-κB and thus are weak inducers of inflammatory cytokines 
[51, 52]. However, IL-17A and IL-17F show a strong synergistic effect when stimulated together 
with other stimuli, including but not limited to TNFα, lymphotoxin (LT), IFNγ, or candidalysin (a 
fungal toxin found in C. albicans) [25, 52, 53]. One of the mechanisms by which IL-17 synergizes 
with other cytokines is to promote mRNA stabilization [54, 55]. Specifically, IB kinase epsilon 
(IKKi) and TBK1-mediated phosphorylation of Act1 recruits TRAF2 and TRAF5 to the Act1:IL-
17R complex. TRAF2 and TRAF5 can sequester the RNA-destabilizing factor ASF/SF2 away 
from the 3’ UTR of at least some target mRNAs, which is best documented for Cxcl1 [56]. 
Furthermore, TRAF2 and TRAF5 also recruit the RNA binding protein (RBP) human antigen R 
(HuR), which leads to the activation of HuR via Act1-dependent ubiquitination. Activated HuR 
then directly binds to the 3’ UTR of client mRNA transcripts and sterically blocks the binding of 
ASF/SF2 [57]. Therefore, removal of ASF/SF2 and the activation of HuR together prevent the 
degradation of target mRNA.  
Due to the proinflammatory role of IL-17-induced signals, negative regulation is critical to 
prevent development of severe inflammatory side effects. One inhibitory mechanism is mediated 
by the C/EBPβ activation domain (CBAD) located in the cytoplasmic tail of IL-17RA (shown in 
Figure 1.2). Deletion of this domain leads to exacerbated IL-17-mediated inflammation [28]. The 
CBAD domain is required for phosphorylation of C/EBPβ through ERK and glycogen synthase 
kinase 3 β(GSK-3β). Phosphorylated C/EBPβ binds to the promoters of IL-17 target genes as a 
 9 
transcriptional repressor, which restricts expression of  IL-17 induced genes, including Il6 and lcn2 
[58]. Additionally, TRAF3 and A20 are two inhibitory factors that associate with the CBAD that 
negatively regulate the IL-17 signaling pathway. By binding to the CBAD domain in IL-17RA, 
TRAF3 blocks the recruitment of Act1 to the receptor complex [59]. A20 is a deubiquitinase that 
is induced by IL-17 signaling. A20 dampens the NF-κB and MAPK pathways by deubiquitinating 
the K63-linked ubiquitin chains on TRAF6 [60, 61]. Therefore, A20 acts as a negative feedback 
regulator of IL-17 receptor signaling via the CBAD region.  
Similar to the post-transcriptional activation of IL-17 target genes, modulating mRNA 
stability is another mechanism to limit IL-17-induced gene expression. Regnase-1, also known as 
the endoribonuclease MCPIP1 (MCP-1-induced protein 1), negatively regulates IL-17 signaling 
by degrading mRNAs. IL-17 promotes Regnase-1 expression via NF-κB and also stabilizes 
Regnase-1transcripts (Zc3h12a) by activating the DEAD box protein DDX3X [62, 63]. Regnase-
1 recognizes and degrades the IL-17-induced mRNA transcripts such as Il6 and Nfkbiz by binding 
to specific stem-loop structures in their 3’ UTR [62]. A 3’ UTR-independent mechanism for 
Regnase-1 function has also been reported, through degradation of Il17ra and Il17rc mRNAs [62]. 
Notably, Regnase-1 is a deubiquitinase (DUB). Through its DUB activity, Regnase-1 removes 
ubiquitin moieties on TRAFs and further inhibits the NF-κB and JNK signaling pathways [64]. 
Additionally, numerous other mRNA binding proteins and microRNAs that promote mRNA decay 




Figure 1.3 Interleukin (IL)-17RA/RC signaling pathways 
IL-17 signaling starts with the interaction between IL-17A, IL-17F, or IL-17AF with the IL-17RA/RC 
receptor complex. Ligand binding to the receptor complex recruits the adapter Act1 through homotypic interactions 
via SEFIR domains. IL-17 signaling upregulates the expression of target genes through promoting mRNA 
transcription and mRNA stability. The mRNA transcription pathway is imitated by Act1, which induces K63-linked 
ubiquitylation of TRAF6, which consequently activates the MAPK, NF-κB, and C/EBPβ, pathways. These pathways 
trigger transcriptional activation of downstream target genes. For the mRNA stability pathway, phosphorylation of 
Act1 recruits TRAF2 and TRAF5, which sequesters the mRNA-destabilizing factor ASF/SF2 and recruits mRNA-
stabilizing factor HuR. TRAF2 also recruits Arid5a upon IL-17 stimulation. Arid5a consequently promotes mRNA 
stability and enhances translation of multiple genes. IL-17 signaling pathways can be negative regulated by multiple 
classes of inhibitors, including ubiquitinases, deubiquitinases, endoribonucleases, kinases. Representative inhibitors 
of each class are indicated. Numerous other activators and inhibitors of IL-17 signaling pathway are reviewed in detail 
elsewhere.   
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1.4 Biological activities of IL-17A and IL-17F  
The principle source of IL-17A and IL-17F is Th17 cells, a subtype of CD4+ T helper (Th) 
cells characterized by expression of IL-17A and IL-17F [65, 66]. In addition to Th17 cells, many 
innate immune cells also secret IL-17A and IL-17F, such as γδ T cells, innate TCRαβ+ cells, Type 
3 innate lymphoid cells (ILC3), natural killer (NK) cells, and NKT cells [67-69]. Th17 cells and 
the innate IL-17A-secreting cells are collectively termed “Type 17” cells, and these populations 
all respond to IL-23 for optimal activation (reviewed in [67]).  
Genetic deletions of IL-23 or IL-17A, or antibodies blocking their function, significantly 
ameliorate the development of autoimmune disease models such as experimental autoimmune 
encephalomyelitis (EAE), indicating a driving role of IL-17A and IL-23 in autoimmunity [66, 70-
72]. Consistent with this, IL-17A is associated with human immune pathology. For example, IL-
17A is increased in synovial fluid of many rheumatoid arthritis patients, IL-17A-secreting cells 
can be found in cerebrospinal fluid of multiple sclerosis patients [73-75], and IL-17A expression 
is detectable in biopsies from skin lesions of psoriasis patients [76]. Based on these and other 
findings, IL-17A-targeted therapies have been developed and show remarkable efficacy in 
psoriasis [77]. Currently, three neutralizing antibody agents that block the functions of IL-17A are 
clinically available (Table 1.1): secukinamab, ixekizumab, and brodalumab.  Secukinamab and 
ixekizumab target IL-17A and to a lesser extent IL-17A/F [78, 79]. Brodalumab blocks IL-17RA, 
thus inhibits IL-17A, AF and F but may also inhibit signaling from other members of the IL-17 
family [80]. Recently, bimekizumab, a monoclonal antibody that selectively inhibits IL-17A and 
IL-17F, was developed (Table 1.1). A phase 3 clinical trial of bimekizumab showed promising 
results in patients with moderate to severe plaque psoriasis [81]. Notably, systemically delivered 
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IL-17-directed therapies have side effects such as recurrent C. albicans infection and inflammatory 
bowel disease (IBD), indicating the protective role of IL-17A in those diseases [82-84].   
Because of the clinical significance of IL-17A and IL-17F, various animal models have 
been used to determine the in vivo functions of IL-17A and IL-17F. Due to the qualitatively similar 
signaling pathways and cellular sources shared by IL-17A and IL-17F, there is much overlap in 
their in vivo biological activities. However, several reports demonstrated a different, even 
somewhat opposing, roles of IL-17A and IL-17F in vivo. Notably, determining the physiological 
function of the IL-17AF heterodimer is challenging, thus its specific role in vivo is mostly 
unknown. The similar yet distinct biological activities of IL-17A and IL-17F are summarized in 
Table 1.2. To delineate the differences between IL-17A and IL-17F in relevant biological settings 
three model systems have been used for the studies in this dissertation, including oropharyngeal 
candidiasis (OPC), DSS-colitis, and autoimmune glomerulonephritis (AGN). Each animal model 
will be discussed in detail below.  
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Table 1.4.1 IL-17 target therapies in psoriasis 
Generic name Target Reference 
Secukinamab IL-17A (IL-17A/F) [79] 
Ixekizumab IL-17A (IL-17A/F) [78] 
Brodalumab IL-17RA [80] 
Bimekizumab IL-17A and IL-17F [81] 
 
 
Table 1.4.2 The biological activities of IL-17A and IL-17F in infectious and inflammatory diseases 
 IL-17A IL-17AF IL-17F Reference 
C. rodentium infections Protective Not determined Protective [85] 
S. aureus mucocutaneous 
infection 
Protective Not determined Protective [85] 
Lung inflammation Pathogenic Not determined Pathogenic [86] 






Pathogenic Not determined Not required [86] 
Autoimmune 
glomerulonephritis (AGN) 
Pathogenic Not determined Pathogenic [88] 
Dextran sulfate sodium 
(DSS)-induced colitis 
Protective Not determined Pathogenic [86, 89] 
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1.4.1 The role of IL-17 signaling in oropharyngeal candidiasis (OPC) 
1.4.1.1 Function of IL-17A; evidence from clinical studies 
Fungal infections are a serious threat to human health, yet do not receive as much attention 
as other pathogens [90]. Approximately 1.7 billion people suffer from superficial fungal infections 
worldwide [91]. Although superficial infections are generally easy to cure, fungi are often life-
threatening upon invasive infection. The number of deaths caused by the top 10 invasive fungal 
pathogens exceeds even than that of tuberculosis and malaria [90].  
Candida albicans is one of the most common disease-causing fungi. C. albicans is a 
commensal microbe that can be found on mucosal surface of most humans. C. albicans usually 
stays benign under healthy conditions but can cause pathogenic infections in settings of 
immunodeficiency, antibiotic use, and extremes of age, among other conditions. CD4+ T cells play 
an important role in the immunity against C. albicans, as 95% of HIV+ patients suffer from 
recurrent C. albicans oral infections during progression to AIDS.  
There is much evidence that human Th17 cells are responsible for preventing mucosal 
infections of C. albicans, demonstrated by clinical data from various cohorts of chronic 
mucocutaneous candidiasis disease (CMCD) [92-95]. For example, patients with IL-17RA, IL-
17RC, and Act1 mutations are susceptible to recurrent mucocutaneous candidiasis [96-99]. 
Similarly, CMCD is associated with STAT3 and RORC mutations that are associated with reduced 
Th17 frequencies [100-102]. Additionally, OPC is a safety concern for IL-17A blockade therapy 
for autoimmune disease, though the incidence is actually quite low. Approximately 2-3% of 
patients who receive anti-IL-17A neutralizing antibodies exhibit recurrent C. albicans oral 
infection [83, 84, 103].  
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1.4.1.2 Lessons from an “experiment of nature” IL-17F deficiency in CMCD patients 
An unusual cohort of rare CMCD patients that harbor a dominant negative mutation of IL-
17F provided fascinating insights into the function of IL-17F, and were the first direct hint that 
there is a protective function of IL-17F and/or IL-17AF in anti-fungal immunity against C. 
albicans. Genetic analysis of CMCD patients revealed a heterozygous serine-to-leucine mutation 
in the IL17F gene at position 65 (IL-17F.S65L) after the leader sequence [99]. Serine 65 in IL-17F 
plays a role in facilitating the binding of IL-17F to the IL-17RA receptor, as the polar side chain 
of serine can interact with K135 of IL-17RA in a water-mediated manner [19]. Replacement of the 
serine with a non-polar leucine residue dampens the binding of the IL-17F to IL-17RA by 
interfering with the interaction between S65 of IL-17F and K135 of IL-17RA. Thus, the mutation 
impairs the binding capacity of IL-17F to its receptor but does not interfere the dimerization of IL-
17F, either with another IL-17F or with IL-17A. In vitro experiments showed that a mutant IL-
17F homodimer (IL-17F.S65L/IL-17F or IL-17F.S65L/IL-17F.S65L) or IL-17A/F heterodimer 
(IL-17F.S65L/IL-17A) failed to activate IL-17 signaling in human fibroblasts, as measured by the 
expression of the target genes IL6 and CXCL1. Notably, IL-17A homodimers were still functional 
in these patients yet were clearly insufficient to fully protect from candidiasis (although the 
incomplete penetration of the IL-17F.S65L mutation may indicate some protective role of the 
remaining IL-17A homodimers). Therefore, the IL-17F.S65L mutation in the CMCD patients 
implied a significant contribution of IL-17F and/or IL-17AF to the antifungal immune response in 
human.  
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1.4.1.3 Animal research predicts clinical outcomes - Understanding IL-17A and IL-17F by 
murine OPC 
Studies in mice by the Gaffen lab predated most of the above human analyses, and first 
demonstrated a role for IL-17 signaling in OPC [104]. Mice lacking IL-17RA, IL-17RC or the 
signaling adaptor Act1 are all highly susceptible to systemic, oral, and dermal candidiasis [36, 
105-108]. Il17a-/- mice or mice treated with IL-17A neutralizing antibodies also show a modestly 
elevated susceptibility after oral challenge of C. albicans, though the fungal burden is significantly 
less than Il17ra-/- and Act1-/- mice [87]. In contrast, Il17f-/- mice are fully resistant to OPC. 
However, mice with IL-17A and IL-17F double deficiency show a higher susceptibility to OPC 
than IL-17A single deficient mice, indicating that IL-17F does participate in immunity to C. 
albicans in the setting of oral infection [87, 109]. Unfortunately, due to a lack of reagents that 
selectively and efficiently block IL-17A/F, the in vivo function of the IL-17A/F heterodimer cannot 
be determined in the murine OPC model.  
1.4.1.4 C. albicans recognition and the induction requirement of type 17 immunity 
A morphological transition from yeast to hyphae is a key driver for C. albicans to induce 
both virulence and the host immune response. Under effective immunosurveillance, C. albicans 
mainly exists in its yeast form and does not trigger detectable signs of disease. Conversely, in an 
immunodeficient condition, C. albicans yeast transition to a hyphal form that induces tissue 
damage and activates antifungal immunity. Mutations in the fungus that block the yeast to hyphae 
transition (such as efg1Δ/Δ cph1Δ/Δ double knockout or eed1Δ/Δ) render C. albicans avirulent in 
mouse models of systemic and oral candidiasis [110, 111].  
For an immune response to be initiated, the immune system first recognizes pathogen 
associated molecular patterns (PAMPs) on infecting microbes (figure 1.4). In C. albicans, the cell 
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wall component β-(1,3)-glucan is a major PAMP. To escape immunosurveillance, C. albicans 
shield their β-(1,3)-glucan in the inner cell wall with an outer layer of a glycosylated 
mannoproteins (mannan). In vivo studies demonstrated that β-glucan is masked at the early stage 
of infection, but becomes exposed and accessible to pathogen recognition receptors (PRRs) during 
the progression of an infection. The unmasking process might be caused by an impaired integrity 
of the mannan layer during the host-pathogen interaction, which might be mediated by innate 
immune cells induced damage. [112, 113].  
Dectin-1 is the main receptor that recognizes β-(1,3)-glucan during an antifungal immune 
response. Dectin-1 on antigen presenting cells (APC) directs the development of adaptive 
immunity by promoting the production of IL-1β, IL-6 and IL-23 via a Syk/CARD9-mediated 
pathway. The production of these cytokines skews the polarization of Th17 cells [114-116]. In 
addition, other PRRs such as TLR2, NLRP3, and NLRP10 are also reported to initiate the immune 
response by recognizing the PAMPs during C. albicans infection [117-122]. Notably, mice lacking 
expression of Dectin1 or Card9 are resistant to OPC, indicating an alternative signaling pathway for 
initiating anti-fungal immunity.  
Another mechanism to initiate anti-fungal immunity is achieved through fungal virulence 
factors, and of particular relevance to this dissertation is Candidalysin (Figure 1.4). Candidalysin 
is an amphipathic pore-forming peptide derived from the hyphal-specific ECE1 gene [123]. 
However, Candidalysin is not needed for hyphal formation, and its activities are separable from 
those of -glucan and other hyphal cell wall components. Upon C. albicans oral infection, 
Candidalysin induces oral epithelial cell damage and promotes the release of IL-1α, IL-1β and IL-
36. IL-1α and IL-1β activate TCRαβ+ cells to promote IL-17A expression. The activation of 
TCRαβ+ cells is mediated by both cell-intrinsic and extrinsic mechanisms, as transferring IL-1R-
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deficient T cells into WT mice or WT T cells into Il1r-/- mice showed a deficient TCRαβ+ cell 
proliferation during OPC  [124]. Despite this, mice with IL-1R signaling deficiency are only mildly 
susceptible to OPC, indicating that other players are involved in antifungal immunity against C. 
albicans oral infection. Our lab also reported that IL-36, another IL-1 family cytokine, activated a 
protective pathway that is distinct from IL-1R-mediated type 17 immunity, as Il36r-/- mice showed 
increased fungal burdens during OPC, without altered expression of IL-17A or IL-17A-dependent 
target genes [125]. Taken together, these findings demonstrate that Candidalysin is an essential 
initiator of type 17 immune responses upon C. albicans oral infection, through IL-1- and IL-36-
family cytokines.  
In addition, Candidalysin promotes the expression of c-Fos, an activating protein-1 (AP-1) 
transcription factor. Incubation with Candidalysin in cultured mucosal epithelial cells results in 
upregulation of c-Fos via a p38-MAPK-mediated pathway [123, 126]. c-Fos appears to be a key 
factor to induce antifungal immunity. In vitro experiments showed that loss of c-Fos in an oral 
epithelial cell line dampens the expression of inflammatory cytokines, including IL-1α, IL-6, and 
G-CSF [127]. In vivo, c-Fos is upregulated by C. albicans hyphae but not C. albicans yeast during 
OPC, suggesting that c-Fos might be a central molecular sensor of the switch between these states 
of the pathogen [128]. However, to date the functional role of c-Fos in vivo has not been explored 
in depth, as a complete c-Fos knockout mouse is embryonically lethal. However, based on our 
studies of Candidalysin, c-Fos is predicted to initiate an effective early response to C. albicans in 
the oral cavity.  
In addition to Candidalysin, the activation of type 17 immune responses in the setting of 
OPC requires the commensal microbiome. Germ free mice show a decreased level of oral resident 
TCRαβ+ cells [129], which are an important cellular source of IL-17A during acute OPC. Indeed, 
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the commensal microbiome is important for anti-fungal immunity, as germ-free mice or mice 
treated with antibiotics showed an upregulated C. albicans gut colonization [130]. Moreover, 
gentamicin treatment leads to an impaired host resistance to C. albicans infection at the ocular 
surface [131]. Therefore, the commensal microbiome is essential for appropriate response of type 




Figure 1.4 Activation of Type 17 immune response during OPC  
Left: C. albicans hyphae secretes Candidalysin during invasion of oral epithelial cells. Candidalysin induces oral 
epithelial damage. This signal promotes the induction of IL-1α and IL-1β, which enhances type 17 immune response 
by activating innate TCRβ+ cells. Candidalysin also promotes the expression of c-Fos, whose in vivo function is not 
well studied yet. Right: antigen presenting cells recognize C. albicans by Dectin 1. Consequently, the production of 
Th17 polarizing cytokines is activated via CARD9-BCL-10-MALT1 signaling pathways. These cytokines facilitate 
the Th17 cell differentiation and activation via transcriptional factor STAT3 and RORγT, which leads to the 
production of IL-17A, IL-17AF, IL-17F and IL-22. 
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1.4.1.5 Oral epithelium: One target site of IL-17 signaling 
The oral epithelium is the first physical barrier to C. albicans infection in the mucosa. 
Disruption of the epithelial barrier promotes fungal susceptibility upon C. albicans oral infection, 
which is demonstrated by autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED) disease. APECED is an inherited autoimmune disease caused by AIRE gene deficiencies. 
APECED patients suffer from only one major infection, CMCD, which was originally attributed to 
circulating autoantibodies against both IL-17A and IL-17F. However, a recent study showed that type 
17 immunity is actually intact in both mice and humans with AIRE deficiency [132]. Instead, enhanced 
production of IFN-γ by type 1 immunity is observed within the oral mucosa of Aire-/- mice as well as 
APECED patients. The overexpression of IFN-γ leads to epithelial barrier disruption, which further 
promotes mucosal fungal susceptibility.  
The oral epithelium is not only a passive physical barrier that limits microbial invasion, but 
also an active site of immunosurveillance. The oral epithelium is compartmentalized into multiple 
layers according to the expression of unique keratins that function to maintain epithelial integrity 
(Figure 1.5) [133]. The basal epithelial layer (BEL) is characterized by keratin 5 (K5) and keratin 
14 (K14) expression. Epithelial stem cells are located in the BEL [134, 135], which makes basal 
epithelial cells highly proliferative. Therefore, BEL is responsible for maintaining epithelial integrity 
and wound repair by replenishing terminally differentiated superficial cells that are sloughed during 
the antifungal immune response [136-138]. Keratin 4 (K4) and keratin 13 (K13) are found in 
intermediate and superficial layers, collectively termed the suprabasal layer. During invasion, C. 
albicans induces epithelial cell damage in the suprabasal layer, which further induces the innate type 
17 response as described above. In turn, IL-17A and IL-17F target the epithelial cells in the suprabasal 
layer to mediate protection to OPC. Conditional knockout of IL-17RA in the K13+ epithelial layer (the 
suprabasal cells) leads to a higher fungal burden and impaired antimicrobial peptides secretion, whose 
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fungal burden is only slightly less Il17ra-/- mice [139]. Therefore, beyond serving as a physical barrier, 
the oral epithelium is a key site for initiation of the innate type 17 response during OPC and it also 
responds to IL-17, by virtue of restricted IL-17RA expression.  
 
 
Figure 1.5 Structure of the oral mucosa  
Keratinizing epithelium of the tongue is compartmentalized into the superficial layer, intermediate layer, and basal 
layer. Intermediate layer and superficial layers collectively are termed a suprabasal layer. Each layer expresses unique 
sets of keratins. The suprabasal layer is characterized by expression of K4 and K13. The expression of K5, K14, and 
K19 is observed in the basal epithelial layer.  
1.4.1.6 Mechanism of IL-17-mediated fungal clearance 
IL-17A promotes fungal clearance through expression of neutrophil-attracting chemokines 
(CXCL1, CXCL2, and CXCL5) and antimicrobial peptides (AMPs, namely β-defensins, lipocalin 
2 and S100A8/9) [105, 139]. Neutrophils are critical for antifungal immunity [136, 140, 141]. Mice 
with neutrophil depletion or lacking CCR2 (a common chemokine receptor) are susceptible to oral 
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infection with C. albicans [141]. During OPC, neutrophil recruitment is partially dependent on IL-
17 signaling, as Il17ra-/- mice show an impaired recruitment of neutrophils to the oral mucosa 
following C. albicans oral challenge [36, 105, 142]. Thus, neutrophils are one of the critical factors 
for IL-17-mediated antifungal immunity. Furthermore, IL-17A-induced antifungal immunity is 
mediated by antimicrobial peptides, which is illustrated by the impaired expression of β-defensin 
1 and β-defensin 3 in Il17ra-/- mice and also by the increased susceptibility to OPC in Defb1-/- and 
Defb3-/- mice [139, 143].  
1.4.2 The role of IL-17 signaling in autoimmunity 
1.4.2.1 IL-17A and IL-17F in inflammatory bowel disease (IBD) 
The gastrointestinal (GI) system provides an environment that is beneficial for the growth 
of extremely rich and diversified microbial flora [144]. The intestinal commensal flora benefits 
the host through metabolism of non-absorbed food components and tuning of the immune system. 
However, pathogenic microorganisms also take advantage of the GI tract for colonization and 
invasion. Therefore, the intestinal immune system mediates effective surveillance against 
pathogenic bacteria but also maintains tolerance to antigens from commensal bacteria. 
Perturbation of this tightly regulated environment can lead to chronic intestinal inflammation. IBD 
is a chronic inflammatory disorder in GI tract, which has two major classifications, ulcerative 
colitis (UC) and Crohn's disease (CD). IBD has a prevalence of 0.3% in industrialized countries, 
including North America, Oceania, and Europe [145]. IBD patients suffer from diarrhea, 
abdominal pain, and rectal bleeding. In addition, clinical studies have revealed a correlation 
between IBD and increased risk of intestinal cancer [146].  
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The intestinal epithelium is a physical barrier to bacterial invasion. Loss of barrier integrity 
leads to a ‘leaky gut’ and may initiate the pathogenesis of IBD. Increased intestinal permeability 
allows microbiome-derived molecules to cross the mucosa where some can induce uncontrollable 
inflammation. Impaired barrier integrity is a characteristic feature of most CD and UC patients 
[147]. Recently, genetic studies identified several mutations in tight junction related genes, such 
as CDH1, LAMB1, and GNA12, in cohorts of UC patients [147-149]. Loss of epithelium integrity 
leads to gut inflammation, including the upregulation of inflammatory cytokines.  
IL-23 is a critical cytokine that mediates the immune response in IBD. GWAS analysis 
illustrated a strong association between UC and IL-23R, a connection that was among the first to 
link the Th17 pathway and human autoimmune disease [150]. Single nucleotide polymorphisms 
in IL-23R have been identified in several independent cohorts of UC patients [150]. Serum IL-23 
is elevated in both UC and CD patients [151-154]. Animal studies further indicated an essential 
role of IL-23 in the pathogenesis of IBD, as IL-23-deficiency significantly alleviated inflammation 
scores in various models of experimental colitis [155-159]. Recently, neutralizing antibodies that 
block IL-23 demonstrated promising results in clinical trials of IBD [160].  
IL-23 is known to upregulate Th17 cells but also acts on unconventional IL-17A-secreting 
cells such as γδT cells, NKT cells, and ILC3 [67, 161]. Notably, a population of IL-17A-producing 
ILCs was reported to mediate intestinal immune pathology through IL-23-dependent signaling 
pathway in CD40-induced colitis models [162]. In agreement with animal studies, an increased 
number of ILC3s was also found in CD patients. Consistent with the upregulation of IL-17A-
producing cells during intestinal inflammation, overexpression of IL-17A has been detected in the 
lamina propria and serum from IBD patients [163]. These data indicated that IL-17A might 
contribute to the pathogenesis of IBD.  
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Surprisingly, in contrast to the clear pathogenic role of IL-23, IL-17A was found to be 
protective in IBD, which was unfortunately illustrated in clinical trials of IL-17A blockade 
therapies on CD patients. Two IL-17 blocking agents, secukinumab (targeting IL-17A) and 
brodalumab (targeting IL-17RA), were evaluated in CD [164, 165]. Both studies demonstrated 
worsening outcomes in patients belonging to the active treatment groups, and trials were halted as 
a result. Preclinical studies in different animal models of IBD showed variable and even somewhat 
contrasting results (Table 1.3).  
In agreement with the results from human studies, the murine DSS colitis model indicated 
a protective role of IL-17A in IBD. Either deletion of the IL-17A gene or administration of 
neutralizing antibodies against IL-17A led to an increased severity of DSS-induced colitis in mice 
[86, 166-169]. Further research revealed that IL-17A protects mice from DSS colitis by 
maintaining intestinal integrity. Mice treated with anti-IL-17A antibodies showed an abnormal 
cellular localization of the tight junction protein occludin. Under physiological conditions, 
occludin is localized to the tight junction complex to regulate intestinal permeability. However, in 
mice treated with anti-IL-17A antibodies, occludin was instead found in the cytoplasm, leading to 
increased intestinal permeability [167]. In a separate report, IL-17A was found to synergize with 
fibroblast growth factor (FGF2) to promote the repair of damaged intestinal epithelium during 
DSS colitis [169]. These results from animal models are consistent with the emerging picture from 
clinical observations that IBD is a side effect of secukinumab treatment. Therefore, the balance of 
data in both mice and humans strongly indicate that IL-17A is protective in colitis. 
Interestingly and surprisingly, IL-17F was reported to exhibit an opposing role in DSS 
colitis, unlike IL-17A. Specifically, Iwakura et al. showed that loss of IL-17F led to decreased, 
rather than increased, susceptibility to DSS colitis, which was ascribed to a specific class of gut 
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bacteria that could promote Treg induction [89]. Sequencing of 16S ribosomal RNA (rRNA) 
revealed a different fecal bacterial profile between Il17f-/- and WT mice. In particular, the 
frequency of one of the main groups of commensal bacteria, Clostridium cluster XIVa (C. XIVa), 
was significantly higher in Il17f-/- compared to WT mice. C. XIVa colonization was shown to 
activate intestinal epithelial cells to express TGFβ, which then promoted the differentiation of Treg 
[170]. An altered balance between Treg cells and T effector cells (Teff) in the GI tract was 
suggested to contribute to the development of IBD in this experimental setting [171]. Therefore, 
the upregulation of C. XIVa in Il17f-/- mice led to an increased number of colonic Tregs, which 
explained the reduced DSS colitis seen in Il17f-/- mice. This finding was concordant with the 
observation in IBD patients that Treg levels are decreased in peripheral blood but increased in the 
intestinal mucosa, consistent with a migration of Treg to the inflamed site [172-174]. Several 
studies in experimental colitis also demonstrate a potent anti-inflammatory action of Treg in IBD 
[175-177].  
All these data suggested that IL-17F, unlike IL-17A, is pathogenic in the setting of DSS 
colitis. However, the mechanism of the different biological activities between IL-17A and IL-17F 
during DSS colitis is still not clear, and remains one of the very few examples where IL-17A and 
IL-17F appear to act in a discordant manner (Table 1.3).  
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Table 1.4.3 Functions of IL-17A in mouse models of IBD 
Treatment Colitis model Effect on colitis Reference 
IL-17A KO DSS Disease worse [86, 167, 169] 
IL-17A antibody DSS Disease worse [166, 168] 
IL-17F KO DSS Disease alleviated [86, 89] 
IL-17A KO T-cell transfer Disease worse [178, 179] 
IL-17A antibody T-cell transfer Disease alleviated [159, 180] 
IL-17A +IL-17F antibody T-cell transfer Disease alleviated [181] 
IL-17F KO T-cell transfer Disease alleviated [89] 
IL-17RA KO TNBS Disease alleviated [182] 
IL-17 receptor fusion protein TNBS Disease alleviated [182] 
IL-17A antibody H. Hepaticus Disease alleviated [183] 
 
1.4.2.2 The role of IL-17 signaling in autoimmune glomerulonephritis (AGN) 
Chronic kidney disease (CKD) is a serious health issue and also a social and economic 
burden. Approximately 10% of the western population is affected by CKD [184]. As the disease 
progresses, patients commonly suffer from end stage renal failure, which requires dialysis or 
transplantation. The kidney is a frequent target of systemic inflammatory and autoimmune 
disorders. Renal involvement is commonly found in many cases of systemic autoimmunity against 
ubiquitous antigens [185]. Less common immune responses specifically against renal antigens 
have also been identified. For example, anti-glomerular basement membrane (anti-GBM) nephritis 
is caused by a specific autoimmune response to this renal antigen [186, 187]. GBM rupture and 
inflammation in glomeruli induce a crescent structure that can be observed in renal biopsies [188]. 
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Chronic autoimmune disease with the presence of crescents in more than 50% of glomeruli is 
defined as crescentic glomerulonephritis [189, 190].  
IL-17A is emerging as a key activator of the renal autoimmune response. IL-17A protects 
the kidney from infectious pathogens such as C. albicans, uropathogenic E. coli, and methicillin-
resistant S. aureus [107, 191-193]. However, IL-17 can be pathogenic if not properly regulated 
and thereby contribute to AGN. Lupus patients exhibit an upregulated serum level of IL-17, 
elevated circulating IL-17-producing cells, and increased IL-17 production from lymphocytes, 
compared to healthy volunteers [194, 195]. In addition, the serum level of IL-17A was increased 
in patients with IgA nephropathy, which was proposed to be pathogenic by inducing the production 
and glycosylation of IgA1 in B cells [196, 197]. Single cell RNAseq analysis from kidney biopsies 
of patients with ANCA-associated glomerulonephritis also revealed a highly enriched tissue 
resident memory T cells with a Th17 gene signature [198]. Therefore, observations in the clinic 
indicated a pathogenic role of IL-17A in AGN.  
Murine models of experimental AGN have been used to evaluate the function of IL-17 
signaling in autoimmune kidney disease (Table 1.4). Il23p19-/-, Il17a-/-, and Il17ra-/- mice in 
various models of AGN demonstrate a requirement of IL-17 signaling for kidney pathogenesis 
[199-201]. During AGN, IL-17A is mostly produced by kidney-infiltrating CD4+ and γδ+ T cells 
in response to kidney injury [201, 202]. Renal tubular epithelial cells (RTEC) are the main target 
cells of IL-17 signaling. Multiple IL-17A target genes, including Il6, Cxcl1, Cxcl5, Ccl20, and 
Lcn2, are involved in process of AGN development. Specifically, IL-6 stimulates tubular atrophy 
and accelerates fibrosis during AGN [203]. CXCL1 and CXCL5 are necessary for neutrophil 
infiltration, which is believed to contribute to kidney pathology [201]. CCL20 is an essential 
chemokine for Th17 cell recruitment, thus establishing a positive feedback loop for IL-17A 
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production [202].  Lipocalin 2 is a major biomarker for kidney damage and is also an active player 
in disease progression, as Lcn2-/- mice showed a dramatical reduction of renal lesions during AGN.   
Although the role of IL-17A in AGN is starting to be relatively well understood, our 
knowledge of IL-17F in this disease is still limited. One study showed that Il17f--/- mice are 
resistant to kidney damage, indicating that IL-17F plays a similar role to IL-17A in AGN models 
[88]. In that study, the lower level of kidney damage in Il17f--/- mice was attributed to decreased 
expression of neutrophil-attracting chemokines. However, because the IL-17F target gene profile 
largely overlapped that of IL-17A, other factors such as Lcn2 and Il6 may also be involved in the 
IL-17F-mediated pathway during AGN. Therefore, further research is required to understand the 
in vivo function of IL-17F during AGN. 
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Table 1.4.4 Animal models of nephritis (adapted from [204]) 








Immune, necrosis Partial [208-211] 










Mice have same genetic defect as 
patients but early crescentic 




IL-17A signaling is essential for immunity against some fungal and bacterial infections. 
Conversely, IL-17A is also a critical pathogenic factor in certain autoimmune diseases. Thirty 
years have been passed since the cloning of IL-17A. However, there are still many questions that 
need to be answered regarding IL-17 signaling, in particular the role of the closely-related cytokine 
IL-17F. IL-17A dimerizes with IL-17F to form IL-17A/F heterodimer. In vitro studies of IL-17A/F 
heterodimer indicated a similar gene induction profile of IL-17A/F compared with IL-17A and IL-
17F[34, 35]. Although the in vivo formation of IL-17A/F heterodimers can be clearly observed, 
the physiological role of IL-17AF is still very unclear. IL-17A and IL-17F activate qualitatively 
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similar signaling, and exert similar biological activities in many animal models, including AGN. 
However, these closely related cytokines exhibit opposite roles in a setting of chemically induced 
colitis. Thus, the mechanisms of IL-17A and IL-17F in vivo function are still not well defined.  
 A mutation in IL-17F, IL-17F.S65L, was identified in a single-family cohort of CMCD 
patients. This “experiment of nature” might help us to further understand the functions of IL-17A 
and IL-17F. The S65 residue in human IL-17F is conserved among many species, including mice. 
Therefore, I created an IL-17F.S65L mutant mouse strain in order to probe the role of IL-17F in 
various diseases. In this dissertation, I use this mutant strain to further demonstrate the role of IL-
17F and IL-17AF in varying systems where IL-17F and IL-17A have similar or differing impacts, 
including OPC (Chapter 3), DSS colitis (Chapter 4), and AGN (Chapter 4). 
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2.0 Methods and Materials 
2.1 Materials 
2.1.1 Mice  
Il17fThy1.1 reporter mice were previously described [219]. Il17ra-/- mice were a gift from 
Amgen. Act1-/- mice were from U. Siebenlist, National Institutes of Health. Il17a-/- mice and Il1f-
/- mice were from Y. Iwakura, Tokyo University of Science, and were described previously [85]. 
Wild-type (WT) mice were from The Jackson Laboratory, Taconic Farms, or generated from 
breeding colonies. All mice were on the C57BL/6 background. Age-matched mice (6–10 week) 
were used for experiments with both sexes in OPC model. Male mice were used in DSS colitis 
model and Female mice were used in AGN model. Experiments were performed in accordance 
with protocols approved by the University of Pittsburgh IACUC and NIAID and followed 
guidelines in the Guide for the Care and Use of Laboratory Animals of the NIH. 
2.1.2 Cell and cytokines 
ST2 cells (murine bone marrow stromal cell line) were cultured in α-MEM (Minimum 
Essential Medium α) supplemented with 1% L-glutamine, 1% Pen-Strep, and 10% FBS. CMT93 
cells (murine colonic epithelial cell line) were cultured in DMEM (Gibco Dulbecco's Modified 
Eagle Medium) supplemented with 1% Pen-Strep, and 10% FBS. Ear derived fibroblast cell line 
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were cultured in DMEM supplemented with 1% Pen-Strep, 50μM β-mercaptoethanol, and 50% 
FBS.  
2.1.3 Antibodies  
Antibodies used are listed in Table 2.1 
Table 2.1.1 List of antibodies 
Antibody Vendor Purpose Catalog# Dilution  
CD3 BioXCell T cell activation BE0001-1  
CD28 BioXCell T cell activation BE0328  
IL-17A BioXCell Cytokine blocking BE0173  
c-Fos Cell Signaling Immunohistochemistry 2250S 1:100 
CD4 BV605 Invitrogen Flow cytometry Q10092 1:500 
CD45 Pacblue Invitrogen Flow cytometry 48-0451-82 1:100 
CD45 AF700 Biolegend  Flow cytometry 103128 1:100 
CD11b AF700 Biolegend Flow cytometry 101212 1:100 
Ly6G PE BD biosciences Flow cytometry 551461 1:100 
Thy1.1 APC Biolegend Flow cytometry 202526 1:100 
TCRβ PE Biolegend Flow cytometry 109207 1:100 
TCRγδ Pacblue Invitrogen Flow cytometry 48-5711-82 1:100 
Foxp3 APC Invitrogen Flow cytometry 17-5773-82 1:100 
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2.1.4 qRT-PCR primers 
Primers for qPCR to determine the enteric bacterium level are listed in Table 2.2, and primers 
for qRT-PCR were purchased from Qiagen and are listed in Table 2.3 
 
Table 2.1.2 List of bacterium qPCR primers 
Bacteria name Forward Reverse 
16S (8F&R357) AGAGTTTGATCMTGGCTCAG CTGCTGCCTYCCGTA 
Clostridium XIVa AAATGACGGTACCTGACTAA CTTTGAGTTTCATTCTTGCGAA 
 
Table 2.1.3 List of commercial qRT-PCR primers 
Gene Symbol Organism Catalogue # 
Cxcl1 Mouse QT00098875 
Cxcl2 Mouse QT00115647 
Defb3 Mouse QT00265517 
Gapdh Mouse QT01658692 
Il6 Mouse QT00098875 
Il17a Mouse QT00103278 
Il17f Mouse QT00144347 
Il22 Mouse QT00128324 
Il33 Mouse QT00135170 





2.2.1 Generation of Il17fS65L/S65L knock-in mice 
Il17fS65L/S65L mice were created by CRISPR/Cas9 by the Transgenic and Gene Targeting 
(TGT) and Innovative Technologies Development (ITD) Cores facility in Department of 
Immunology, University of Pittsburgh. Briefly, a S.py. Cas9 target sequence overlapping the Ser65 
codon in the mature Il17f sequence (following signal peptide cleavage) was selected: 
GTTCCCCTCAGAGATCGCTG AGG. The protospacer adjacent motif (PAM) in bold was not 
included in the sgRNA. Cas9 mRNA and the sgRNA were produced as described [220, 221].  A 
127-mer oligonucleotide (Ultramer, IDT) was used as template for homology-directed repair 
(HDR): Il17f-S65L-HDRv3: 5’-CATCCTGCTTTACTTTTTATTTTTTTCCTTCAGCATCACT-
CGAGACCCCCACCGGTTCCCTCTAGAAATCGCTGAGGCCCAGTGCAGACACTCAGG
CTGCATCAATGCCCAGGGTCAGGAAGACAGC-3’. The oligonucleotide contains a 
substitution to convert Serine 65 to Leucine, which contemporaneously breaks an HPY188I 
restriction site (underlined) to facilitate genotyping. The sequence also contains an additional silent 
substitution, bringing a total of 4 mismatches (red, above) between the sgRNA target sequence 
and the designed allele, thus limiting further re-editing of the mutant allele by Cas9. C57BL/6J 
embryos were microinjected with the sgRNA (50 ng/µl), the HDR oligonucleotide (0.5 µM) and 
Cas9 mRNA (100 ng/µl). Embryos that developed to the 2-cell stage were transferred into 
pseudopregnant female surrogates. Five homozygous founders were identified by PCR 
amplification of the target region (Forward: 3’-ATGGGAGAAACCCCGTTTTA-5’; reverse: 3’- 
TCCAACCTGAAGGAATTAGAACA-5’) followed by restriction digestion of the PCR product 
with HYP188I. The correct sequence was validated by Sanger sequencing of the PCR products 
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following TOPO cloning. Potential off-target sequences of the target sequence were identified 
using the CRISPOR website [220]. There were only 2 potential off-target sequence with fewer 
than 4 mismatches in the mouse genome (Table 2.4). There were no mutations introduced at those 
sites, as determined by PCR and Sanger sequencing. The line was backcrossed twice to C57BL/6J 




















Table 2.2.1 Off-target screening of Il17fS65L mutant mice 
aTwo off-target sites with up to 3 bp mismatches were predicted in creation of Il17fS65L/S65L mice, located on 
chromosomes 3 and 5. Precise locations and sequences are shown.  
bPCR primers used to amplify and sequence these regions are indicated. See Materials and Methods section for 
details. 
N/A, not applicable. 
 Off Target 1a Off Target 2a 
Score 0.958618437118 0.455082125604 
Chromosome 3 5 
Start 131,315,589 141,241,627 
End 131,315,611 141,241,649 
Strand - + 
Target Pattern GTTCCCCTCAGAGATCGCTGAGG GTTCCCCTCAGAGATCGCTGAGG 
Mismatch 3 3 
Sequence GTTCTGTTCAGAGATCGCTGTGG GCTCCCCTCACAGAGCGCTGCGG 
Mismatch Location 5, 6, 7 2, 11, 15 
Target Number 1 1 
Target Strand + + 
Mmismatchln2 1 1 
Region Intergenic Exonic 
GeneUCSCID N/A Uc009ail.2 
GeneSymbol N/A Sdk1 
Primer-forwardb AGCTCCAATAAGGCCACACC CACCTGGTGTCGTCCCAC 
Primer-reverseb CACGAGGACTAGACAGCGAC CTCCGATGAGCAGCGAGC 
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2.2.2 Model of OPC 
C. albicans (WT or indicated mutant strains) were inoculated in 10 ml yeast extract peptone 
dextrose (YPD) and incubated for 14-16 hours at 30 ℃ with continuous agitation. The C. albicans 
suspension was prepared for a final cell density of 2 × 107 cells/ml, which is determined by a 1.2 
OD value (wavelength = 600nm) via BioTek Plate Reader. During the C. albicans oral challenge, 
mice were anesthetized by 15 mg/ml ketamine and 1.5 mg/ml xylazine with a dose of 6.7x weight 
of the mouse + 20 ul via intraperitoneal injection (i.p.). The fully anesthetized mice were 
sublingually inoculated by 2.5 mg cotton balls that saturated with the previously prepared C. 
albicans suspension for 75 minutes. Sham mice were similarly inoculated with the same type of 
cotton balls saturated with PBS. Before and after the oral challenge, the mice were also treated 
with 1ml of 0.9% saline by subcutaneous injection. 200 ug/ml anti–IL-17A or isotype control 
antibodies (BioXCell) were administered i.p. on days -1, 1, and 3 relatives to C. albicans infection. 
The mice weights were monitored daily. The mice were harvested at day 1, day 2, and day 5 for 
different experiment purpose. On day 1, One longitudinal half of the tongue were harvested, flash 
frozen in liquid nitrogen and stored at -80ºC for RNA extraction. The other half of the harvested 
tongue were fixed in 10% formalin for paraffin embedded sections preparation. On day 2, the 
harvested tongues were longitudinally cut by half. The half of the harvested tongues were flash 
frozen in liquid nitrogen and stored at -80ºC for RNA extraction. The other half of the tongues 
were processed for flow cytometry.  On day 5, the longitudinal half of the tongue were 
homogenized by gentleMACS system (C-tubes, program E, Miltenyi Biotec). 100ul of the tongue 
homogenates were plated on YPD agar plates containing ampicillin. The plates were incubated at 
30 ℃ for 48 hours, and the colonies on plates were enumerated to estimate the colony forming 
units per gram (CFU/g) of tongue.  
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2.2.3 Leukocytes isolation and enrichment from tongue tissues 
The harvested tongues were chopped into small piece and digested with 500 ul of DNase1 
(1mg/ml, Roche), and Collagenase IV (0.7mg/ml) in HBSS at 37°C for 30 minutes. The single cell 
suspensions were filtered by 70 μm cell strainer and separated by Percoll gradient centrifugation 
with 40% percoll diluted in PBS. 
2.2.4 Flow cytometry 
The single cell suspensions were stained with 1:500 GhostDye Violet 510 (TONBO 
Biosciences, CA) in PBS to exclude dead cells. The indicated fluorescent tagged antibodies (table 
2.1) targeted on surface markers were diluted in FACS buffer with a dilution factor 1:100. The 
surface maker was stained with diluted antibodies on ice for 20 minutes or overnight. If the 
intracellular staining is required, the cells were permeabilized by Foxp3/Transcription factor 
staining buffer set (Invitrogen) for 45 minutes at 4 ℃. The intracellular antibodies were 1:100 
diluted in permeabilization buffer, and stained the cells for 30 minutes at 4 ℃. Data were acquired 
on an LSR Fortessa and analyzed with FlowJo (Tree Star). 
2.2.5 RNA extraction, Quantitative PCR and RNAseq  
For frozen tissues, the harvested tissue was homogenized in 500μl of Qiazol lysis buffer 
(Qiagen) by a GentleMACS Dissociator (M-tubes, program RNA-02, Miltenyi Biotec). The 
homogenate was thoroughly mixed with chloroform, and the mixture was centrifuged for 20 minutes. 
The upper aqueous layer was collected for further RNA isolation following manufacturer’s protocol of 
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the RNeasy Mini Kit (Qiagen). For cultured cell samples, cells were homogenized in 350 ul of RLT 
buffer by vortex. The cell homogenates were used for RNA extraction by RNeasy Mini Kit (Qiagen) 
following manufacturer’s protocol. Total RNA concentration was determined by Nanodrop and 
normalized to 200 ng/ml. 500 ng or 1000 ng of RNA was used for reverse transcription into cDNA. 
cDNA synthesis was performed via Superscript III First-Strand synthesis system (Invitrogen) by 
following the manufacturer’s protocol. Relative quantification of mRNA expression was determined 
by real-time PCR with Perfecta SYBR Green FastMix ROX (Quanta BioSciences) normalized to 
Gapdh on a 7300 Real-Time PCR System (Applied Biosystems). All primers were commercially 
purchased from QuantiTect Primer Assays (Qiagen) and are listed in Table 2.3. For RNASeq, cDNA 
libraries preparation and RNAseq was performed by the Health Sciences Sequencing Core at the 
University of Pittsburgh. The RNAseq results were analyzed by Partekflow software. Specifically, the 
trimmed Sequencing reads were aligned to the UCSC mouse reference genome (mm10, GRCm38.75) 
using STAR. The aligned reads were quantified to annotation model, and the differential gene 
expression was determined by GSA analysis.   
2.2.6 IL-17RA deficient cell line development 
Ears were harvested from Il17ra-/- mice and disinfected with 70% ethanol. The harvested 
ears were chopped into small piece and digested with 950 ul of collagenase 1 in DMEM at 37°C 
for 3 hours with continuous agitation. The single cell suspensions were filtered by 70 μm cell 
strainer and seeded into 6-wells-plate with DMEM containing 50% FBS. The FBS concentration 
in medium is decreased to 30 % after 3 days and further decreased to 20% at day 6 post seeding. 
The primary cells were immortalized by transfection of 2μg SV40 Large T Ag expression plasmid 
with Fugene HD (Promega) when the cell number reached to 6 × 104 cells/well.  
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2.2.7 IL-17F and IL-17F.S65L activation 
Murine ST2 cells, CMT93 cells, and ear derived fibroblasts were seeded into 6-wells-plate 
with a total number of  6 × 104 - 8 × 104 cells. The cells were cultured for overnight to reach a 
60-80% confluence. IL-17F (Peprotech or Bon Opus) or IL-17F.S65L (Bon Opus) were used to 
activate the cells for 3 hours or 6 hours. Murine TNFα were added to make a final concentration 
as 2 ng/ml for synergy effect. The cells were harvested by trypsin treatment and stored in -80 ℃ 
for future RNA extraction 
2.2.8 Th17 differentiation and ELISA 
Total spleen was homogenized in 10 ml PBS using bottom of a 5 ml syringe. The cell 
suspension was passed through a 70 μm cell strainer, and the red cells were lysed by ACK lysis 
buffer (Gibco). CD4+ T cells were isolated from the cell suspensions using CD4+ T cells isolation 
kit (Miltenyi Biotech, cat# 130-104-454). 2 × 105 CD4+ T cells were plated into flat bottom 96-
wells-plate that is pre-coated with anti-CD3 and anti-CD28 antibody (5 μg/ml each) at 4 ℃ 
overnight. Naïve CD4+ T cells were differentiated into Th17 cells by complete RPMI medium 
containing Th17 cocktails (IL-1β 50ng/ml, IL-6 50ng/ml, IL-23 50ng/ml, TGFβ 5ng/ml). Th0 
control were treated only with complete RPMI medium. After 4 days, supernatant was collected, 
and the concentration of IL-17A was determined by murine IL-17A ELISA kit (eBioscience). 
ELISA were performed following manufacturer’s protocol. Samples were analyzed in triplicate 
for each experiment.  
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2.2.9 Histology and Immunohistochemistry 
Paraffin section of formalin fixed tongue tissues were processed by Histology Core facility 
of the University of Toledo Medical Center. Paraffin embedded sections were stained as described 
in the Cell Signaling immunofluorescence protocol (https://www.cellsignal.com/learn-and-
support/protocols/protocol-ihc-paraffin). Briefly, the paraffin section was deparaffinized by 
incubating with xylene and rehydrated by incubating with 100% ethanol followed by another 
incubation with 95% ethanol. The antigen was unmasked by steaming the section in 10 mM sodium 
citrate buffer (pH 6.0). 5% normal goat serum in TBST was used to block the section for 1 hour at 
room temperature. Samples were stained overnight with primary antibodies, c-Fos (clonal: 9F6, 
Cell Signaling 2250S), and subsequently incubated with secondary antibodies for 30 minutes at 
room temperature. The staining was developed by incubating with ABC reagent (Vectastain ABC 
Kit, Vector Laboratories) for 30 minutes followed by another incubation with DAB Reagent 
(Vector Labs). Images were obtained on an EVOS FL microscope (Life Technologies). 
2.2.10 Model of DSS colitis and FITC-Dextran Administration 
2% or 2.5% of DSS (MP bio) were dissolved into drinking water and gave to mice for 7 
days. Mice weight and disease activity index score were monitored daily. The disease activity 
index score was the combined score of weight loss, stool consistency, and bleeding, which can be 
defined as follow: Weight loss: 0 (no loss), 1 (1-5%), 2 (5-10%), 3 (10-20%), and 4 (>20%); Stool 
consistency: 0 (normal), 2 (loose stool), and 4 (diarrhea); Bleeding: 0 (no blood), 2 (visual pellet 
bleeding), and 4 (gross bleeding, blood around anus). At the time point of choice, the mice were 
sacrificed, colon length was measured, and the colon tissues were harvested for flow cytometry or 
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stored in -80°C for qPCR. Oral gavage of FITC dextran was used to determine the gut epithelial 
integrity during DSS colitis. Briefly, at day 7 of DSS treatment, mice were off-fed for 4 hours, and 
FITC dextran (Sigma-Aldrich, catalog number: FD4) was administered to each mouse 
(40mg/100gram body weight, 200 microliter volume) via oral gavage with a needle attached to a 
1 ml syringe. After 4 hours, mice were anesthetized and the blood was collected via cardiac 
puncture into an EDTA-coated tube. Plasma was separated by centrifuging the blood containing 
EDTA-coated tube at 5000 rpm for 20 min. The concentration of FITC in plasma was measured 
by BioTek Plate Reader with an excitation of 485 nm (20 nm band width) and an emission 
wavelength of 528 nm (20 nm band width).  
2.2.11 Colonic lamina propria cell isolation 
The colon tissue was “butterfly” opened and cut into 0.5-1cm pieces. Epithelial cells were 
stripped by stirring the colon tissue with RPMI buffer complement with 3% FBS, 5mM EDTA 
(Invitrogen), and 1mM DTT (Invitrogen) for 20 minutes at 37°C. The tissue sample was shaken 
in RPMI containing 2mM EDTA to further wash out the epithelial cells. Colonic tissue was then 
incubated in a digestion cocktail containing complete RPMI with 0.5mg/ml DNase and 20μg/ml 
liberase (Roche) at 37°C for 25 minutes. Digested tissue was processed through a 70μm cell 
strainer and a 40μm cell strainer. The single cell suspension is continued for flow cytometry.  
2.2.12 Fecal bacterium isolation and enteric C. XIVa determination 
Fecal samples were collected before the DSS treatment. Stools were homogenized by a 
1000 μl peptide tip, and the DNA of fecal bacterium was isolated by following manufacturer’s 
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protocol of the QIAamp Fast DNA Stool Mini Kit (Qiagen). Relative quantification of Clostridium 
XIVa DNA was determined by real-time PCR with Perfecta SYBR Green FastMix ROX (Quanta 
BioSciences) normalized to the amount of total bacteria (16S) on a 7300 Real-Time PCR System 
(Applied Biosystems). 
2.2.13 Model of anti-GBM nephritis 
Rabbit IgG (0.1 mg/ml) and complete Freund’s adjuvant were emulsified at 1:1 ratio. Mice 
were immunized with the mixture of rabbit IgG + CFA by i.p. injection on day -3. On day 0, Serum 
containing anti-glomerular basement membrane antibodies was i.v. injected to Il17fS65L/S65L mice, 
Il17a-/- mice, Il17f-/- mice, as well as WT mice. On day 14 post i.v. injection, mice were euthanized 
and blood were harvested via cardiac puncture. Blood was incubated at 4°C overnight in a tilted 
position, and serum was collected in the next day. Blood urea nitrogen (BUN) was determined by 
Blood Urea Nitrogen Enzymatic Kit (Bioo scientific, cat# 5602-01) following manufacturer’s 
protocol. 
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3.0 An Il-17F.S65L knockin mouse reveals similarities and differences in IL-17F function 
in oral candidiasis: A new tool to understand IL-17F 
This is the author’s version of the work. Sections of this chapter have been adapted from 
the original work published in Journal of Immunology and is posted here with permission from the 
journal. 
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IL-17A and IL-17F exert similar yet distinct activities during OPC.  Il17a-/- mice or mice 
treated with IL-17A-neutralizing antibodies exhibit elevated susceptibility to OPC compared to 
immunocompetent control mice [87], whereas Il17f-/- mice or WT mice treated with IL-17F 
neutralizing antibodies are fully resistant to C. albicans infection. However, there is evidence that 
IL-17F does participate in immunity to OPC, as dual blockade of IL-17A and IL-17F increases 
susceptibility to OPC over blockade of IL-17A alone [87, 109].  
The physiological role of IL-17AF is still unclear. Although IL-17AF can be reliably 
detected (e.g., by sandwich ELISA), there are no commercial antibodies that block this isoform 
selectively and efficiently, and hence determining its specific role in vivo is challenging. Hints 
regarding IL-17F and IL-17AF function came from an unusual cohort of CMCD patients 
discovered by Puel et al. that carry a heterozygous serine-to-leucine mutation in the Il17f gene at 
position 65 (IL-17F.S65L) [99]. This mutated residue lies within the region of interaction between 
IL-17F and the IL-17 receptor. In vitro, this mutation impaired IL-17F binding to the receptor, but 
had no apparent impact on the ability of IL-17F to dimerize with IL-17F or IL-17A. Cultured 
human fibroblasts treated with an IL-17F homodimer containing this mutation (IL-17F.S65L/IL-
17F or IL-17.S65L/IL-17F.S65L) or a mutant IL-17AF heterodimer (IL-17A/IL-17F.S65L) 
showed strongly impaired signaling in vitro [99]. Accordingly, the S65L substitution in human IL-
17F appeared to be both a loss of function and a dominant negative mutation, causing functional 
blockade of both IL-17F and IL-17AF. Importantly, IL-17A homodimers were still found in these 
patients, yet were unable to fully protect against candidiasis. These data thus implied that IL-17F 
and/or IL-17AF are significant contributors to the antifungal immune response in humans. 
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As described in this chapter, I created an IL-17F.S65L mouse strain using CRISPR/Cas9 
technology to exploit this “experiment of nature,” [99] in order to better understand the functions 
of IL-17F and IL-17AF in immune responses. We found that Il17fS65L/S65L mice exhibited similar 
susceptibility to OPC as Il17a-/- mice, which contrasted with the known resistance of Il17f-/- mice 
to OPC [87]. Thus, S65K appears to be more than simply a loss-of-function mutation. The 
increased susceptibility of these mice to fungal infection was linked to impaired expression of 
CXC chemokines and concomitantly reduced neutrophil recruitment to the oral mucosa. but 
surprisingly not to expression of key antimicrobial peptides known to control OPC, such as β-
defensin-3. Similar to IL-17A, IL-17F is expressed by -T cells, innate TCRαβ+ cells, and 
possibly also by ILC3s. Previous research indicated that type 17 immunity is orchestrated by 
Candidalysin during acute OPC, and may be influenced by the commensal microbiome [124, 129]. 
Here, I found that the commensal flora is essential for antifungal immunity for C. albicans oral 
infection. In contrast, c-Fos, an important mediator of the Candidalysin-induced signaling 
pathway, surprisingly appears not to be required for fungal clearance during OPC.  
3.2 Results 
3.2.1 Murine IL-17F S65L is a loss-of-function mutation 
The S65L residue in IL-17F which is mutated in humans with CMCD is conserved among 
many species, including mice [99]. The human IL-17F.S65L cytokine has no apparent signaling 
capacity in vitro [99]. To determine whether the mouse orthologue of IL-17F.S65L functions 
similarly to its human counterpart, a His-tagged murine IL-17F.S65L and a corresponding WT IL-
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17F control, were expressed in Expi293 cells and purified from conditioned media on nickel-
charged affinity resin (Ni-NTA) (Figure 3.1A). Recombinant IL-17F.S65L and IL-17F migrated 
according to their predicted dimeric sizes on a non-reducing SDS-PAGE gel (Figure 3.1B). The 
multiple bands observed in the reduced (R) and non-reduced (NR) gels are consistent with the 
expectation that these recombinant cytokines exist in multiple glycosylated and non-glycosylated 
forms (Figure 3.1B, Figure 3.2). 
To evaluate the signaling capability of murine IL-17F.S65L, murine ST2 stromal cells were 
treated with increasing concentrations of IL-17F.S65L or WT IL-17F for 3 hours. Two IL-17F-
inducible genes, Il6 and Cxcl1, were assessed by qPCR as endpoints of signaling. As expected, a 
wild type version of IL-17F induced Il6 and Cxcl1 expression in a dose-dependent manner (Figure 
3.1C). In contrast, IL-17F.S65L at most dosages (6.25-50 ng/ml) did not detectably upregulate Il6 
or Cxcl1. Expression of these genes was slightly enhanced by IL-17F.S65L at a supraphysiological 
dose (100 ng/ml), but nonetheless showed significantly reduced activity compared to non-mutated 
IL-17F (Figure 3.1C). Because IL-17F synergizes with other cytokines to induce gene expression 
[28, 32], we evaluated IL-17F.S65L responsiveness to a suboptimal dose of TNFα (2 ng/ml). 
Control IL-17F synergized with TNFα to induce Il6 and Cxcl1, but IL-17F.S65L did not 
synergistically enhance expression of these genes (Figure 3.1D). Thus, analogous to the IL-

























































































































Figure 3.1 Murine IL-17F.S65L is a loss-of-function mutation 
(A) Amino acid sequences of recombinant His-tagged WT IL-17F and the IL-17F.S65L mutant used in this study. 
The Ser65 residue is shown in red. (B) IL-17F and IL-17F.S65L were transfected into Expi293 cells. Culture medium 
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was collected on day 5 post transfection purified by Ni-NTA. The eluted fraction was analyzed by SDS-PAGE in 
reducing (R) condition and non-reducing (NR) conditions. Size markers are indicated at left. (C, D) ST2 stromal cells 
were treated with the IL-17F (blue) and IL-17F.S65L (red) at increasing doses in the absence (C) or presence (D) of 
TNFα (2 ng/ml) for 3 h. Il6 or Cxcl1 mRNA was assessed by qPCR. Data is graphed as fold-change relative to 




Figure 3.2. Glycosylation site prediction in murine IL-17F 
The IL-17F amino acid sequence (see Figure 3.1) 1 was analyzed for predicted N-glycosylation sites (NetNGlyc 1.0 
server). Asn-X-Ser/Thr sequences are shown in blue, and Asn residues predicted to be N-glycosylated are shown in 
red. + potential > 0.5, ++ potential > 0.5 and jury agreement (9/9) or potential > 0.75. 
3.2.2 Il17fS65L/S65L mice are modestly susceptible to OPC 
To determine the function of the murine IL-17F.S65L mutation in vivo, we created an IL-
17F.S65L mutant mouse strain by CRISPR/Cas9 technology. Sixteen founders were generated, 5 
of which had a homozygous nucleotide replacement (Figure 3.3A, Figure 3.4). None of the founder 
lines were found to have mutations in either of the two predicted off-target sites, ascertained by 
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PCR of genomic DNA and sequencing (Table 2.4). Similar to Il17a-/- and Il17f-/- mice [85], there 
were no obvious abnormalities in the health of these mice when maintained in specific pathogen 
free (SPF) conditions, and they bred normally with Mendelian numbers of offspring. 
In the family of patients where the S65L substitution was identified, 5/7 of the affected 
individuals experienced CMCD as heterozygotes (no homozygotes were described [99]), and thus 
we hypothesized that mice that are either homozygous or heterozygous for the IL17F.S65L 
mutation would be susceptible to mucosal candidiasis. Accordingly, mice were subjected to OPC 
by a 75-minute sublingual exposure to C. albicans (strain CAF2-1) by standard methods [222, 
223]. In this model, WT mice typically clear C. albicans from the oral mucosa within 3 days and 
show no overt signs of illness, such as prolonged weight loss [105, 139]. We previously 
demonstrated that mice lacking IL-17RA or Act1 maintain a high fungal burden in the oral cavity 
after infection, which we typically measure at day 5 post infection (p.i.) [105, 106], Mice lacking 
IL-17A (Il17a-/- or given anti-IL-17A antibodies) have detectable fungal burdens, though 
consistently lower than Il17ra-/- or Act1-/- mice [87]. In contrast, mice lacking IL-17F (Il17f-/- or 
given anti-IL-17F antibodies) are fully resistant to OPC, at least within the detection limits of this 
system [87]. Here, we observed that Il17fS65L/S65L mice had significantly higher oral fungal burden 
compared to WT controls at 5 days p.i., at levels similar to those in Il17a-/- mice (Figure 3.3B). 
However, the Il17f+/S65L heterozygous mice did not have elevated fungal loads compared to the 
WT mice. Approximately 40% of the Il17fS65L/S65L and Il17a-/- mice still had a detectable fungal 
load at this time point, whereas almost all the WT and the Il17fS65L/+ heterozygous mice fully 
cleared the infection (Figure 3.3C). Il17fS65L/S65L mice also lost slightly more weight than the WT 
mice, which was most evident at day 2 p.i. (Figure 3.3D, E). However, oral fungal burdens in 
Il17fS65L/S65L mice were not measurably different at day 2 (Figure 3.3F). Collectively, these results 
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indicate that IL-17F.S65L mutation contributes detectably, albeit modestly, to susceptibility to 




Figure 3.3 Il17fS65L/S65L mice are modestly susceptible to OPC 
(A) Top: Schematic diagram of murine IL-17F.S65L substitution created by CRISPR/Cas9 including breaking of a 
new IHPY188I restriction site. Bottom: Representative chromatogram of genomic DNA sequencing from a 
representative founder mouse. (B) The indicated mice were infected sublingually with C. albicans or PBS (Sham). 
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Fungal burdens were assessed by CFU enumeration on YPD/Amp on day 5 p.i. Graphs show geometric mean + SD. 
Dashed line indicates limit of detection (~30 CFU/g). Data were compiled from five 5 experiments. Each symbol 
represents one mouse. (C) Data from panel B is represented as percentage of mice with detectable fungal load in the 
tongue. Values above indicate number of mice with fungal burden/total. (D) Weight in the animals from panel B was 
assessed daily and percentage loss relative to day 0 is shown for each time point. (E) Weight loss of Il17fS65L/S65L and 
WT mice at day 2 p.i. from panel B. Graph shows mean ± SD. (F) Fungal burdens were assessed on day 2 p.i.. Data 
are compiled from 3 independent experiments. Data were analyzed by ANONVA or Student’s t-test, with Mann-
Whitney analysis for fungal load analysis. *P < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. 
 
 
Figure 3.4 Genomic DNA sequencing of IL-17F.S65L mutation 
Founder mice were created by CRISPR/Cas9. Genomic DNA of founders was extracted from tail tissue and subjected 
to sequencing. (A) DNA sequence of mice with an Il17f S65L/S65L homozygous mutation. Black dot indicates nucleotide 
replacement. (B) Chromatogram of the DNA sequence data showed in panel A. 
3.2.3 Il17fS65L/S65L mice show mildly impaired neutrophil recruitment during OPC 
To understand the immunological mechanisms by which the IL-17F.S65L mutation 
promotes susceptibility to OPC, we evaluated factors known to be critical for antifungal immunity 
that are mediated by IL-17R signaling [36, 105, 139]. Neutrophils are vital for fungal clearance in 
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OPC [140, 141, 224]. We have observed that Il17ra-/- mice show impaired recruitment of 
neutrophils to the oral mucosa following OPC induction [36, 105, 142]. IL-17F upregulates 
expression of neutrophil-attracting chemokines such as CXCL1 and CXCL2 [86, 88, 225], and 
both human and murine IL-17F.S65L showed impaired induction of these chemokines in vitro 
(Figure 3.1, [99]). Consistent with this, Cxcl1 gene expression in the tongue was downregulated 
in Il17fS65L/S65L mice during C. albicans oral infection, though not completely impaired. However, 
expression of Cxcl2 was similar between Il17fS65L/S65L mice and WT controls (Fig. 3.5A). Flow 
cytometry analysis revealed that early neutrophil recruitment to the tongue measured at day 2 p.i. 
was partially decreased in infected Il17fS65L/S65L mice, compared to WT (45% versus 57%) (Fig. 
3.5B). There was also a trend towards reduced total numbers of neutrophils, though there was high 
variability in the number of cells recovered from the tongue (a common problem often encountered 
when isolating cells from this tissue [124, 226]). Thus, although not yet proven directly, impaired 
neutrophil recruitment in Il17fS65L/S65L mice may help explain OPC susceptibility in these mice. 
Antimicrobial peptides (AMPs) such as β-defensins and calprotectin (S100A8/S100A9) 
have antifungal activity towards C. albicans [143, 227-230]. IL-17RA knockout mice show 
impaired AMP expression following C. albicans oral challenge [105, 139]. Surprisingly, the 
induction of Defb3 and S100a9 in the oral mucosa of Il17fS65L/S65L mice was equivalent to that in 
the WT upon oral C. albicans infection (Figure 3.5C). Therefore, the increased susceptibility to 
OPC in Il17fS65L/S65L mice is apparently not due to insufficient AMP expression. Moreover, these 
data suggest that IL-17F and/or IL-17AF signaling may be more critical for the neutrophil response 






Figure 3.5 IL-17F.S65L mice exhibit impaired neutrophil recruitment during OPC  
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The indicated mice were infected sublingually with C. albicans or PBS (Sham). (A) Tongues were harvested at day 2 
p.i.. Total mRNA from tongue homogenates was assessed by qPCR, normalized to Gapdh.  Fold change compared to 
Sham is indicated. Graphs show mean + SEM. Data were merged from 2 independent experiments. (B) Single cell 
suspensions from tongues harvested at day 2 p.i. were analyzed by flow cytometry. Cells were gated on the CD45+ 
live cell population and stained for CD11b and Ly6G. Left: representative FACS plots. Right: compiled results from 
3 independent experiments. Graph shows mean ± SEM. (C) Total mRNA from tongue homogenates was assessed for 
Defb3 (encoding β defensin 3) and S100a9 by qPCR, normalized to Gapdh.  Relative expression data are graphed as 
mean ± SEM merged from 4 independent experiments. Data were analyzed by ANOVA. *P < 0.05, **P< 0.01. 
3.2.4 Increased OPC in Il17fS65L/S65L mice is not due to impaired IL-17A 
IL-17A promotes antifungal activity in response to OPC [87, 231]. To determine if IL-17A 
expression was impacted in Il17fS65L/S65L mice, we assessed Il17a mRNA from tongue at day 2 p.i, 
a time point at which IL-17A normally peaks [142]. Interestingly, Il17fS65L/S65L mice showed 
elevated levels of both Il17a as well as Il17f compared to controls (Figure. 3.6A), suggesting that 
the higher fungal susceptibility in Il17fS65L/S65L mice is not likely due to impaired Il17a expression; 
rather, the mildness of disease susceptibility in these mice may be due to compensatory increases 
in IL-17A levels. To determine whether increased Il17a expression is directly caused by the IL-
17F.S65L mutation in T cells, we subjected splenic CD4+ T cells to in vitro differentiation for 3 
days under Th17 conditions (IL-6, IL-23, TGFβ). IL-17A concentrations in culture supernatants 
were measured by ELISA. As shown, there was no significant difference in the amount of IL-17A 
produced by T cells obtained from Il17fS65L/S65L, Il17f-/- or WT mice (Figure 3.6B). Thus, IL-
17F.S65L does not directly cause an increase in IL-17A production in T cells.  
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Figure 3.6 The IL-17F.S65L mutation does not influence IL-17A production from T cells 
The indicated mice were infected sublingually with C. albicans or PBS (Sham). (A) At 2 days p.i., total mRNA was 
isolated from tongue and Il17a and Il17f measured by qPCR and normalized to Gapdh. Data show mean ± SEM from 
4 independent experiments. (B) Naïve CD4+ T cells from indicated mice were isolated from spleen and activated with 
anti-CD3 and anti-CD28 antibodies (5 ug/ml) under Th17 conditions (IL-1β, IL-6, IL-23 at 50 ng/ml and TGFβ at 5 
ng/ml) for 4 days. IL-17A in supernatants was measured by ELISA. Data were analyzed by ANOVA. *P < 0.05. 
 
To determine if the elevated IL-17A seen production in the tongue could compensate for 
IL-17F signaling in Il17fS65L/S65L mice, we treated mice with neutralizing antibodies against IL-
17A [231] following OPC induction. In WT mice, blockade of IL-17A resulted in increased fungal 
burdens and an increased percentage of mice with fungal loads, measured at day 5 p.i., as 
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previously demonstrated (Figure 3.7A, B) [87]. However, IL-17A blockade in Il17fS65L/S65L mice 
did not further increase the oral fungal load compared to Il17fS65L/S65L isotype control mice or WT 
mice treated with α-IL-17A antibodies (Figure 3.7A, B). Thus, in contrast to findings in Il17f-/- 
mice [87], IL-17A does not compensate for the IL-17F.S65L mutation during OPC. 
 
 
Figure 3.7 IL-17A does not compensate for IL-17F signaling in Il17fS65L/S65L mice during OPC 
The indicated mice were infected sublingually with C. albicans or PBS (Sham). (A)  Mice were injected i.p. with α-
IL-17A neutralizing Abs or isotype control IgG (200ug) on days -1, 1, and 3 relative to the infection. CFU was 
determined on day 5 p.i.. Data were compiled from 2 independent experiments. (B) Data from panel A is represented 
as percentage of mice with detectable fungal loads. Values above indicate number of mice with fungal burden/total. 
*P ˂ 0.05 by ANOVA and Mann-Whitney analysis. 
3.2.5 IL-17F is produced dominantly by γδ T cells 
Unlike humans, mice do not harbor C. albicans as a commensal microbe. Multiple studies 
have verified that the initial immune response to an oral C. albicans infection in mice is derived 
entirely from a rapid innate-like response [109, 124, 129, 232-234]. The predominant sources of 
IL-17A during acute OPC were previously shown to be unconventional, innate-like TCRαβ+ and 
 60 
γδ-T cells [124, 129]. ILC3s were reported to produce IL-17A as well [109]. Using Il17fThy1.1 
reporter mice [219], we observed increased levels of Il17f-expressing cells 2 days after C. albicans 
infection (Figure 3.8A), the time point at which Il17f mRNA expression peaks [87]. γδ-T cells 
constituted the majority of the Thy1.1+ population (64%), and TCRβ+ cells also comprised a 
significant portion of the Thy1.1+ cells (21%). A population of TCRγδ-negative TCRβ- negative 




Figure 3.8 IL-17F is dominantly produced by oral γδ-T cells during OPC 
Il17fThy1.1 reporter mice were subjected to OPC. At day 2 p.i., single cell suspensions from tongue were analyzed by 
flow cytometry. (A) Cells were stained for Thy1.1 (a reporter for IL-17F) and CD45 in the live lymphocyte gate. Left: 
representative FACS plots. Right: compiled results from 2 independent experiments. (B) Single cell suspensions from 
panel A were stained for TCRβ and TCRγδ in the CD45+ Thy1.1+ gate. Left: representative FACS plots. Right: 
compiled results from 2 independent experiments. Data were analyzed by ANOVA or Student’s t-test. ***P < 0.001, 
**** < 0.0001. 
3.2.6 The intestinal microbiome is required for fungal clearance during OPC 
Microflora are known to regulate host immune responses. In the oral cavity, the commensal 
microbiome is required for the development or recruitment of innate-like TCRαβ+ cells, because 
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innate-like TCRαβ+ cells are not detectable in germ-free mice [129]. Given the fact that innate-
like TCRαβ+ cells are one of the major cellular sources of IL-17A and IL-17F during OPC (Figure 
3.8B, [124, 129], I hypothesized that commensal flora are essential for IL-17-mediated antifungal 
immunity against C. albicans oral infection. To interrogate the contribution of the microbiome 
during OPC, germ-free mice were subjected to OPC for 5 days. In support of my hypothesis, germ-
free mice demonstrated a significantly higher fungal burden compared to the WT specific pathogen 
free (SPF) mice (Figure 3.9). Notably, the fungal burden of germ-free mice at day 5 post infection 
was comparable to Act1-/- mice under SPF conditions, possibly indicating a loss of IL-17 signaling 
in germ free mice upon C. albicans oral infection (Figure 3.9).  
Colonization of a single commensal microbe, segmented filamentous bacterium (SFB), in 
the small intestine induces Th17 cells in the lamina propria [235]. Therefore, I predicted that 
reconstituting SFB in germ-free mice would induce an oral type 17 immune response and thus 
promote fungal clearance during OPC. Accordingly, fecal pellets collected from SFB 
monocolonized mice were homogenized in PBS and introduced into germ-free mice by oral 
gavage. The mice treated with SFB were then challenged by C. albicans oral infection 14 days 
later. As expected, mice with SFB reconstitution were showed a reduced fungal burden compared 
to the PBS control under germ free conditions (Figure 3.9). Therefore, a single commensal 




Figure 3.9 Commensal microbiome is essential for antifungal immunity during OPC 
The indicated mice were subjected to OPC under germ-free or SPF conditions. The indicated mice with a age of 6 
weeks were treated with SFB or PBS via oral gavage on -14 day relative to infection. Fungal burdens were assessed 
by CFU enumeration on YPD/Amp on day 5 post infection. Graphs show geometric mean ± SD. Dashed line indicates 
limit of detection (~30 CFU/g). **P ˂ 0.01 by Mann-Whitney analysis. 
3.2.7 c-Fos is not required for protection against C. albicans oral infection 
During the early stages of a C. albicans oral infection, activation of innate type 17 
immunity is dependent on Candidalysin secretion by C. albicans hyphae. c-Fos is upregulated by 
Candidalysin in cultured mucosal epithelial cells, such as the buccal oral epithelial cell line TR146 
as well as A431 vulvovaginal cells [123, 236]. In addition, c-Fos has been reported to mediate the 
immune response to Candidalysin or C. albicans hyphae in vitro, as c-Fos deficiency in TR146 
cell lines led to decreased expression of proinflammatory cytokines (IL-1α, IL-1β, IL-6, G-CSF, 
and GM-CSF) after treatment with Candidalysin or C. albicans hyphae [124, 127]. Thus, I 
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hypothesized that c-Fos may be required for mounting this early innate type 17 response to OPC. 
First, we examined c-Fos expression within the oral mucosa by immunohistochemistry (IHC). As 
shown, c-Fos is expressed tonically in the BEL of the tongue (Figure 3.10A). After infection with 
C. albicans, expression is also seen in the suprabasal SEL, starting at 8 hours p.i. and sustained for 
at least 24 hours (Figure 3.10A). Expression was not seen after infection with the yeast-locked 
(nonvirulent) Egf1Δ/Δ strain of C. albicans (Figure 3.10B), suggesting that the yeast-hyphal 
transition is needed to induce c-Fos expression in the oral epithelium. Thus, c-Fos is induced 
rapidly in the oral epithelium following infection with C. albicans in a hyphal-dependent manner. 
 
Figure 3.10 c-Fos expression at oral epithelium during OPC 
(A) WT mice were subjected to OPC. Mice tongues were harvested at 4, 8, and 24 hours post infection, and c-Fos 
expression was analyzed by immunohistochemstiry (IHC). SEL and BEL are indicated by dashed lines and indicated 
by red arrows. (B) WT mice were orally challenged with Efg1Δ/Δ strain (yeast-locked) or revertant strain of C. albicans 
as indicated. c-Fos was stained by IHC at 24 hours post infection.  
In order to elucidate the function of c-Fos in in the superficial oral epithelium during OPC, 
we crossed fosfl/fl mice to mice expressing the Cre recombinase under control of the murine keratin 
13 (K13) promoter (CfosK13). This system (created by our lab) drives expression of Cre 
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recombinase in lingual, buccal, esophageal and vaginal epithelial cells, without expression in skin 
or intestinal epithelia [139, 142]. We confirmed that inducible expression of c-Fos in the SEL was 
absent in these mice at 24 hours p.i. (Fig 3.11A).  CfosK13 mice were infected sublingually with C. 
albicans, and weight loss and oral fungal burden were assessed at day 5. Sham (PBS)-infected WT 
mice and Il17ra-/- mice were used as negative and positive controls for infection clearance, 
respectively. As expected, WT mice fully cleared C. albicans by day 5 p.i., whereas Il17ra-/- mice 
maintained oral fungal burdens. To our surprise, the CfosK13 mice were fully resistant to OPC, 
showing no weight loss or fungal clearance that was indistinguishable from WT mice (Figure 
3.11B). As noted, resistance to OPC in mice requires a type 17 immune response, characterized 
by expression of a panel of innate immune cytokines. As shown, infected CfosK13 mice showed 
normal induction of Il17a, Il22, Il6 and AMPs such as S100A9 (Figure 3.11C). 
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Figure 3.11 c-Fos is not required for antifungal immunity during OPC 
The indicated mice were infected sublingually with C. albicans or PBS (Sham). (A) c-Fos expression was analyzed 
by IHC at 24 hours post infection. (B) Total mRNA was extracted from tongue homogenate at 24 hours post infection. 
mRNA expression of Il17a, Il22, Il6, and s100a9 was assessed by qPCR and normalized to Gapdh. (C) Left: Mice 
weight was assessed daily and percentage loss relative to day 0 is shown for each time point. Right: Fungal burdens 
were assessed by CFU enumeration on YPD/Amp on day 5 p.i. Graphs show geometric mean ± SD. Dashed line 
indicates limit of detection (~30 CFU/g) 
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3.3 Discussion 
C. albicans asymptomatically colonizes healthy individuals and typically only causes 
mucocutaneous infections in immunocompromised individuals [237, 238]. Deficits in IL-17 
signaling or Th17 cell development are linked to superficial C. albicans infections [101, 239].  
Although CMCD patients with null mutations in genes encoding IL-17RA, IL-17RC or ACT1 
have all been described, no CMCD patients have been reported with a single IL-17A deficiency 
thus far [100]. Even anti-IL-17A biologics used to treat autoimmune disease cause only a modest 
increase in mucocutaneous Candida infections [103, 240]. 
In general, observations in mouse models of OPC have been accurate predictors of the 
immune correlates in oral candidiasis, especially with regards to the IL-17 axis [36, 105, 241, 242]. 
Mice treated with IL-17A neutralizing antibodies have lower fungal burdens compared to the 
Il17ra-/- mice during OPC [87, 231], which parallels the low percentage of patients who experience 
mild C. albicans mucocutaneous infections during secukinumab or ixekizumab treatment [78, 79, 
103, 240]. Unlike humans [93, 243], laboratory mice do not harbor C. albicans as a commensal 
organism, and hence the acute OPC model system reflects events in the innate response [124, 125, 
129, 232]. Nonetheless, mice generate potent and protective recall Th17 responses to C. albicans 
after a secondary encounter, similar to humans [232, 233, 244]. Humans with STAT3 mutations 
experience CMC [101], and although STAT3 is not required in CD4+ cells to protect from OPC, 
we recently found that STAT3 is essential in oral epithelium [129, 142]. Mice express different 
AMPs than humans do, especially in the saliva [245, 246]. Of relevance to C. albicans infections, 
the AMP β-defensin 3 is essential to prevent OPC in mice [139], though this protein has no direct 
orthologue in humans [247, 248].  
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Although humans with the IL-17F.S65L mutation were only described in a single kindred, 
the degree to which the phenotype of Il17fS65L/S65L knockin mouse is similar or different from 
humans is a matter of interpretation. While mice with a complete IL-17F deficiency do not 
recapitulate the CMC phenotype found in humans with the IL-17F.S65L mutation, mice with the 
analogous IL-17F mutation do exhibit OPC in the homozygous state, pointing to similarities 
among species. Puel et al. reported that 70% of the individuals carrying the IL-17F.S65L mutation 
(5/7) had a confirmed diagnosis of mild CMCD [99]. In contrast, almost all the Il17fS65L/+ mice 
fully cleared C. albicans from the mouth and were statistically indistinguishable from WT controls. 
However, susceptibility was seen in mice carrying the mutation on both alleles, contrasting with 
the lack of susceptibility previously documented in Il17f-/- mice [87]. This observation could be 
interpreted to mean there is no dominant-negative activity of this mutation in mice. However, the 
CFU enumeration system used to quantify OPC likely underestimates the actual number of 
infectious fungi, since Candida albicans hyphae are not easily separable into single cells and hence 
each colony may represent more than a single organism [249]. The finding that fungal 
susceptibility in Il17fS65L/S65L mice more closely resembled that in Il17a-/- mice than that in Il17f-/- 
mice may imply there is some level of dominant-negative activity that the OPC model cannot 
sufficiently detect [87]. Additionally, there is one other report of a human IL-17F mutation, but 
unfortunately the nature of the mutation was not provided, so no functional inferences can be made 
[250]. 
Blocking IL-17A together with IL-17F increases susceptibility to OPC, compared to 
blockade of IL-17A alone [87, 109]. However, administration of IL-17A neutralizing antibodies 
(which also efficiently block IL-17AF [87]) in Il17fS65L/S65L mice did not further increase 
susceptibility to OPC, suggesting that residual IL-17A homodimers present in these mice do not 
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provide additional detectable protection. Clearly, there is more to learn about the role of IL-17F in 
antifungal immunity. 
Taken together, the above results are consistent with a protective role for the heterodimer 
IL-17AF in OPC, which has been challenging to determine due to a paucity of reagents to study 
the heterodimer. Studies in human fibroblasts showed that the IL-17F.S65L mutation impaired 
signaling of both the IL-17F homodimer and the IL-17AF heterodimer [99]. The increased 
susceptibility to OPC in Il17fS65L/S65L mice could be due either to a contribution of IL-17F 
homodimer and/or the IL-17AF heterodimer. Nonetheless, neutralization of IL-17F did not cause 
an increase in fungal loads in WT mice [109], suggesting that a deficiency of the IL-17AF 
heterodimer rather than (or in addition to) IL-17F could be responsible for increased fungal loads 
in Il17fS65L/S65L mice. A protective role of IL-17AF could also explain why IL-17A blockade failed 
to further promote fungal infection in Il17fS65L/S65L mice. If IL-17AF is indeed the primary effector 
cytokine among the three IL-17RA/IL-17RC receptor ligands, the increased susceptibility to OPC 
caused by anti-IL-17A treatment could be due to blockade of IL-17AF rather than the IL-17A 
homodimer, as generally assumed [87]. Since Il17fS65L/S65L mice have a fully impaired IL-17AF 
signaling pathway, this could explain why anti-IL-17A antibody treatment did not lead to higher 
fungal burden than isotype control antibodies.  
An unexpected observation made in these studies was that the IL-17F.S65L mutation 
affected CXCL1 mRNA expression and subsequent neutrophil recruitment in the setting of OPC, 
yet had no detectable impact on expression of the key antifungal AMPs, β-defensin 3 and 
S100A8/A9 (calprotectin). IL-17 is a potent regulator of the neutrophil axis, acting on target 
epithelial cells to induce chemokines that in turn recruit CXCR2-expressing neutrophils, among 
other myeloid cells [141]. It is unclear if this moderate suppression of neutrophils accounts for the 
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susceptibility phenotype in mice with the S65L mutation. In fact, not all studies of OPC have found 
that IL-17 regulates neutrophil infiltration during C. albicans infection [251]; the reason for the 
discrepancy among laboratories is unclear, but could possibly relate to effects of different local 
oral microbiota [252, 253]. 
Host-microbiota interactions play important roles in modulating the immune response, 
which is particularly prominent in antifungal immunity. Disruption of the oral microbiome by 
broad spectrum antibiotic therapy has been shown to increase proportions of C. albicans [254]. 
Similarly, mice treated with antibiotics show elevated fungal burdens during OPC [252]. Here, I 
further elucidated the role of the microbiome in mucosal C. albicans infections, showing that 
germ-free mice are highly susceptible to OPC at levels similar to mice with IL-17 deficiency.  
Notably, SFB reconstitution in germ-free mice reversed the increased fungal burden during 
OPC. SFB is a commensal microbe commonly found in the gut of mice. Intestinal colonization of 
SFB has been shown to skew mucosal effector T cells to a Th17 dominated milieu [235]. Thus, 
the protective function of SFB during OPC might be mediated by upregulation of the type 17 
immune response in oral mucosa. It should be noted that conventional, adaptive, Th17 cells are 
not activated during a first encounter with OPC, even in mice with a specific pathogen free (SPF) 
microbiome. Instead, innate TCRαβ+ cells and γδ T cells are major cellular sources of IL-17A and 
IL-17F during primary C. albicans oral infections [124, 129]. The colonization of innate TCRαβ+ 
cells in the oral mucosa requires existence of commensal microbiota, as tongue tissue of germ-free 
mice showed a decrease in TCRαβ+ cells [129]. Thus, the impaired fungal clearance in germ-free 
mice during OPC may be caused by a lack of oral mucosa-resident TCRαβ+ cells, and 
reconstitution of SFB promotes fungal clearance by driving TCRαβ+ cells to occupy a niche in the 
oral mucosa. 
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 In agreement with this, intestinal colonization of SFB has been reported to induce 
inflammation in non-intestinal tissues. For instance, germ free mice that are normally resistant to 
EAE develop robust disease after monocolonization with SFB [255]. Presence of SFB in the gut 
can also protect mice from acute methicillin-resistant Staphylococcus aureus (MRSA) lung 
infection [256]. Therefore, intestinal colonization of SFB might similarly promote antifungal 
immunity against C. albicans in oral mucosa. However, I could not yet rule out the possibility that 
oral resident SFB could directly induce type 17 immune responses in the oral mucosa, an issue 
that will need to be explored further.  
The activation of innate type 17 immunity against C. albicans is also attributed to 
Candidalysin, a virulence factor secreted by C. albicans hyphae. Candidalysin induces the immune 
response by stimulating oral epithelial cells to secrete IL-1α/β, which promotes proliferation of 
innate TCRαβ cells for IL-17 signaling [124]. c-Fos is a transcription factor that is upregulated 
upon candidalysin activation in an OEC line, TR146 [123]. TR146 cells lacking c-Fos showed an 
impaired immune response upon the in vitro challenge of C. albicans [127]. Thus, c-Fos appeared 
to be an important factor in Candidalysin-induced immunity against C. albicans. Based on this, I 
predicted that Candidalysin-induced c-Fos expression is critical for fungal clearance during OPC. 
Although I found that c-Fos is expressed in SEL in a C. albicans hyphae-dependent manner, loss 
of c-Fos in SEL surprisingly did not impact fungal clearance during OPC. Notably, Candidalysin 
not only activates the downstream c-Fos signaling pathway, but also damages OECs. Thus, 
damage-induced IL-1α/β expression might compensate for the loss of c-Fos in OECs during oral 
C. albicans infections. Furthermore, a single point mutation in Candidalysin, Ece1-III62–93AA, is 
shown to activate c-Fos expression, but does not induce cell damage in vitro. The mutant peptide 
could still activate the non-damage associated cytokine G-CSF, but failed to induce expression of 
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IL-1α. This may indicate that a damage-dependent pathway, rather than c-Fos signaling, 
contributes to Candidalysin-mediated IL-1α/β secretion.   
Although the IL-17RA/IL-17RC heterodimer is the canonical receptor complex thought to 
transduce signaling in response to IL-17A, IL-17F and IL-17AF [21, 42], several alternative 
configurations of the receptor have been recently proposed. IL-17RD was suggested by Chen 
Dong’s group to act in keratinocytes in concert with IL-17RA to mediate IL-17A signaling, but 
not IL-17F signaling, to drive psoriasis-like skin inflammation [24]. Thus far, the binding capacity 
of IL-17AF to an IL-17RA/RD receptor complex has not been characterized. In the OPC model, 
Il17rc-/- mice phenocopy Il17ra-/- mice in terms of fungal loads and other aspects of disease [36], 
suggesting that IL-17RC is needed to mediate immunity. Il17rc-/- mice are also susceptible to 
dermal candidiasis [257]. Likewise, humans with IL17RC null mutations experience CMCD [98]. 
Hence, it is unlikely that an IL-17RC-independent receptor complex mediates host-defense during 
mucocutaneous candidiasis.  
A recent structural analysis of the IL-17RC subunit unexpectedly revealed that IL-17F may 
have the ability to signal through an IL-17RC homodimeric receptor [258], though this would 
contrast with our prior molecular studies showing that a forced dimer of murine IL-17RC is not 
signaling-competent [28]. Interestingly, the binding site of S65 in IL-17F was shown to be located 
on IL-17RA [19]. A mutation on this residue is likely to impair the binding activity of IL-17F to 
IL-17RA rather than IL-17RC, so changes in binding affinity to IL-17RC homodimeric receptor 
would likely be less pronounced [23]. Putting this together, we speculate that the increased fungal 
burden in Il17fS65L/S65L mice is caused by reduced interactions of IL-17F with the IL-17RA/IL-
17RC heterodimer, rather than with the IL-17RC homodimeric receptor (see detailed discussion 
of these receptors in Chapter 5.2).  
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In summary, results from this new IL-17F.S65L mutant mouse strain in the murine OPC 
model are generally, though not completely, in line with findings in CMCD patients with the IL-
17F.S65L mutation. These data help reconcile the observations that, whereas a complete IL-17F 
deficiency does not promote candidiasis in mice, this naturally occurring IL-17F mutation in 
humans does. The potential utility of this new mouse strain goes beyond studies of candidiasis. 
Because these mice show a different phenotype from Il17f-/- mice with respect to OPC, they could 
be a valuable tool to interrogate the functions of IL-17F and the enigmatic IL-17AF heterodimer 
in other settings where these cytokines may participate, such as DSS colitis and AGN. 
 74 
4.0 Divergent functions of IL-17-family cytokines in autoimmune disease:  Lessons from a 
naturally occurring human mutation in IL-17F 
4.1 Background 
IL-17A and IL-17F exert similar yet distinct in vivo biological activities, which is 
illustrated by their roles in OPC (Chapter 3). In this chapter, I focus on using the IL-17F.S65L 
mice to define the in vivo functions of IL-17F in two autoimmune disease models, DSS colitis and 
AGN. Whereas IL-17A and IL-17F were reported to have opposite roles during DSS colitis [86, 
89], Il17a-/- mice and Il17f-/- mice showed a similarly resistant phenotype in an AGN model [88].   
In the DSS colitis model, IL-17A and IL-17F appear to have very different biological 
activities. Multiple groups have demonstrated that Il17ra-/-, Il17a-/- and mice treated with IL-17A 
neutralizing antibodies all show exacerbated DSS colitis. This phenotype has been attributed to 
reduced intestinal repair [86, 166-168]. Consistently, in humans, IBD is a side effect of anti-IL-
17A biologics for treatment of psoriasis [240]. In addition, clinical trials for IL-17A targeting 
therapies have been halted due to worsening outcomes in CD patients [164, 165]. Taken together, 
all these data suggest a protective role of IL-17A during DSS colitis.  
In contrast, loss of IL-17F in the murine DSS colitis model led to an improved outcome, 
suggesting that IL-17F is pathogenic in this setting [86, 89]. The resistant phenotype of Il17f-/- 
mice during DSS colitis was attributed to regulation of enteric microbiota [89]. Specifically, 
Clostridium cluster XIVa was reported to be upregulated in Il17f-/- mice, leading to increased levels 
of intestinal resident Tregs, which are known to be responsible for controlling DSS- induced 
inflammation. Therefore, IL-17A and IL-17F function in an opposing manner during DSS colitis, 
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but the mechanism for this dichotomy is not well understood, and will be discussed here. 
With respect to AGN, Il23p19-/-, Il17a-/-, and Il17ra-/- mice demonstrated a pathogenic role 
of IL-17A in various AGN models. Consistent with these findings, observations from clinical 
studies indicated that circulating IL-17A and the number of IL-17A-producing cells are 
upregulated in patients with chronic kidney disease, including IgA nephropathy, lupus nephritis, 
and ANCA-associated glomerulonephritis. These hint at a pathogenic function of IL-17A in human 
diseases. Multiple IL-17A target genes are involved in this process, which leads to direct kidney 
damage, tubular atrophy, fibrosis formation, and neutrophil recruitment during the development 
of AGN. The physiological function of IL-17F is not as well understood as IL-17A, in AGN 
models. There is one report indicating that Il17f-/- mice are resistant to anti-GBM nephritis, which 
is consistent with the phenotype of Il17a-/- mice in the same settings. Neutrophil-attracting 
chemokines, such as CXCL1 and CXCL5, were found to be decreased in Il17f--/- mice in the anti-
GBM nephritis model, which might contribute to the protective phenotype of Il17f-/- mice. 
Therefore, different from DSS colitis model, data thus far indicate that IL-17A and IL17F exhibit 
similar biological activity in AGN. However, relatively little is known about this process, and 
drugs targeting IL-17/Th17 cells have not been used under these conditions. 
IL-17F.S65L, a naturally-occurring mutation in IL-17F (see Chapter 3), may be a useful 
tool to understand the functional differences between IL-17A and IL-17F. The mouse IL-17F.S65L 
mutation appears to be mainly a loss-of-function mutation in vitro, as the IL-17F.S65L variant 
showed reduced activation of IL-17F target genes such as Cxcl1 and Il6 (Figure 3.1) [99]. However, 
the impact of the IL-17F.S65L mutation goes beyond a loss of IL-17F function in vivo. As 
described in Chapter 3, Il17fS65L/S65L mice demonstrated more C. albicans susceptibility more 
similar to Il17a-/- mice than to Il17f-/- mice. Thus, given the fact that a single point mutation in IL-
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17F could cause an Il17a-/--like phenotype in vivo, we aimed to elucidate the phenotype of 
Il17fS65L/S65L mice in disease models in which IL-17A and IL-17F behave differently, in comparison 
to those where IL-17A and IL-17F share similar biological activities. Therefore, in this chapter, 
Il17fS65L/S65L mice were tested in DSS colitis and AGN. In agreement with the findings in the OPC 
setting, Il17fS65L/S65L mice showed a similar phenotype to Il17a-/- mice during DSS colitis. In 
contrast, the IL-17F.S65L mutation did not have any impact on the development of AGN. Details 
of these systems are discussed in detail in the following sections. 
4.2 Results 
4.2.1 IL-17A and IL-17F play opposing roles in DSS colitis 
As noted, IL-17A was reported to be protective but IL-17F was pathogenic in DSS colitis 
[86, 89]. To determine the mechanistic basis for this difference between IL-17A and IL-17F, I used 
the above-described Il17fS65L/S65L mice in the DSS-induced model of colitis. Importantly, the 
enteric microbiota exert a major influence on outcomes of intestinal inflammation [259]. Thus, the 
phenotype of mice with DSS-induced intestinal epithelial damage can vary considerably across 
facilities. Before evaluating the phenotype of Il17fS65L/S65L mice in DSS colitis model, I confirmed 
the respective functions of IL-17A and IL-17F in DSS colitis in our hands. Il17a-/-, Il17f-/-, or WT 
controls (C57BL/6), were given 2% DSS in drinking water for 7 days. Weight was recorded daily, 
and colon length was measured upon sacrifice on day 10 post-treatment. Consistent with prior 
reports, mice lacking IL-17A (Il17a-/-) or IL-17RA (Il17ra-/-) lost significantly more weight than 
WT control mice, with most requiring sacrifice by day 8 for humane reasons (Figure 4.1A). 
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Commensurate with this, colon lengths of Il17a-/- mice were markedly shorter than WT mice 
(Figure 4.1B). Thus, as previously reported, IL-17A signaling through IL-17RA is protective in 
DSS colitis [86, 89, 166-168].  
IL-17F also signals through IL-17RA, yet Il17f-/- mice did not lose as much weight as WT 
mice upon DSS treatment (Figure 4.1A), and Il17f-/- colons were significantly longer than WT 
colons at day 10 (Figure 4.1C). Therefore, and in agreement with previous reports, IL-17F is 




Figure 4.1 Inhibition of IL-17A and IL-17F showed opposite phenotypes in DSS-induced colitis.  
The indicated mice were treated with 2% DSS-containing water for 7 days. The DSS-containing water was replaced 
with normal drinking water for another 3 days. (A) Body weight was monitored daily and the percentage relative to 
starting weight was shown for each time point. Mice with more than 25% weight loss were sacrificed for humane 
reason. Data were compiled from 5 experiments (B) Colon lengths of Il17a-/- mice were determined at day 8 post 
treatment. (C) Colon lengths of Il17f-/- mice were measured at day 10 post treatment. Data were compiled from 3 
experiments. Each dot (B, C) represents an individual mouse. Graph shows mean ± SEM. Data were analyzed by 
student t test. *P < 0.05, **P < 0.01.  
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4.2.2 Il17fS65L/S65L mice showed an increased susceptibility in DSS colitis 
Humans with an IL-17F.S65L mutation were identified on the basis of susceptibility to 
OPC, and the sequence surrounding this residue is highly conserved in mice [99]. IL-17F.S65L 
dimers (present in both mouse and human) are non-functional at physiological cytokine 
concentrations [99]. As shown in Chapter 3, Il17fS65L/S65L mice showed a susceptibility profile to 
OPC that was more similar to that of Il17a-/- mice than Il17f-/- mice, suggesting that the IL-
17F.S65L mutation may in some way interfere with IL-17A function. Since DSS colitis is one of 
the few known conditions where IL-17A and IL-17F exhibit opposing phenotypes, we assessed 
the impact of this mutation in the context of intestinal inflammation. Accordingly, Il17fS65L/S65L 
mice were administered 2% DSS in drinking water, and scored for disease severity based on weight 
loss, stool consistency and rectal bleeding for 9 consecutive days. Upon sacrifice, colon length was 
measured. Strikingly, DSS treatment consistently caused Il17fS65L/S65L mice to lose more weight, 
exhibit higher disease scores, and have shorter colon lengths than WT mice (Figure 4.2A-C). Thus, 
as we observed during OPC, the Il17fS65L/S65L mice resembled IL-17A-deficient mice rather than 
IL-17F-deficient mice.  
We next sought to understand the basis for susceptibility to DSS colitis in these settings. 
In Il17a-/- mice, susceptibility has been attributed in part to a loss of intestinal epithelium integrity, 
as discussed in details in Chapter 1.4.2.1 [167, 169]. To determine whether the Il17fS65L/S65L mice 
and Il17a-/- mice share a similar mechanism to promote colitis severity, Il17fS65L/S65L mice and WT 
control mice were orally treated with FITC-Dextran after 7 days of DSS treatment to measure gut 
epithelium integrity. Unexpectedly, Il17fS65L/S65L mice showed a similarly elevated FITC-Dextran 
concentrations compared to WT mice (Figure 4.2D). These data indicated that intestinal epithelium 
integrity is not attributable to increased DSS-induced inflammation in Il17fS65L/S65L mice, which 
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differs from findings in Il17a-/- mice.   
 
 
Figure 4.2 Il17fS65L/S65L mice are susceptible to DSS-induced colitis 
The indicated mice were treated with 2% DSS-containing water for 7 days. The DSS-containing water was replaced 
with normal drinking water for another 2 days. (A) Body weight was monitored daily and the percentage relative to 
starting weight was shown for each time point. Mice with more than 25% weight loss were sacrificed for humane 
reason. (B) The disease scores were assessed daily and calculated based on weight loss, anal bleeding and stool 
consistency. (C) Colon lengths of Il17a-/- mice were measured at day 9 post DSS treatment. Each dot represents an 
individual mouse. Graph shows mean ± SEM. (A-C) Data were compiled from 3 individual experiments (D) Mice 
were oral gavaged with FITC-dextran at day 7 post DSS treatment. Mice were harvested 4 hours after oral gavage and 
plasma concentration of FITC-dextran was calculated. Each dot represents an individual mouse. Graph shows mean 
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± SEM. Data were compiled from 2 individual experiments. Data were analyzed by student t test. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001.  
4.2.3 Decreased colonization of intestinal Clostridium cluster XIVa in Il17fS65L/S65L mice 
IL-17F promotes pathogenesis in DSS colitis, and the damaging effect of IL-17F was 
reported to be caused by increased burden of Clostridium cluster XIVa in the colonic epithelium 
specific microbiota [89]. Therefore, I hypothesized that cohousing Il17fS65L/S65L mice with Il17f-/- 
mice would enhance the C. XIVa burden in Il17fS65L/S65L mice, and thus protect Il17fS65L/S65L mice 
against DSS-induced inflammation. To test this hypothesis, Il17fS65L/S65L mice were cohoused with 
Il17f-/- mice for two weeks, followed by another week of 2% DSS treatment. Surprisingly, 
cohousing Il17fS65L/S65L mice with Il17f-/- mice did not alter the susceptibility of DSS colitis in 
Il17fS65L/S65L mice (Figure 4.3B). Instead, the cohoused Il17f-/- mice showed greater weight loss, 
compared to their non-cohoused littermates (Figure 4.3A). Consistent with this, the colons of 
cohoused Il17f-/- mice were shorter than the non-cohoused controls (Figure 4.3B). To further 
explore this unexpected observation, I analyzed the C. XIVa burdens in stools collected prior to 
initiating DSS treatment. The fecal C. XIVa levels from Il17fS65L/S65L mice were lower than WT 
mice, which might contribute to the increased severity of DSS in Il17fS65L/S65L mice. However, in 
contrast to the previous report [89], the levels of C. XIVa in Il17f-/- mice and WT mice were 
comparable (Figure 4.3C). Notably, C. XIVa levels in the cohoused Il17f-/- mice were significantly 
lower than those in non-cohoused littermates but were comparable to levels of C. XIVa in 
Il17fS65L/S65L mice. Collectively, these data indicated that intestinal microbiota, likely via the 
Clostridium cluster XIVa, positively correlated with enhanced signs of intestinal inflammation in 
Il17fS65L/S65L mice.   
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Figure 4.3 The commensl C. XIVa population is reduced in Il17fS65L/S65L mice 
Il17fS65L/S65L mice and WT mice were cohoused for 2 weeks. The indicated mice were subjected for DSS treatment for 
7 days. The DSS-containing water was replaced with normal drinking water for another 3 days. (A) Body weight was 
monitored daily and the percentage relative to starting weight was shown for each time point. Mice with more than 
25% weight loss were sacrificed for humane reasons. (B) Colon lengths of the indicated mice were determined at day 
10 post DSS treatment. Each symbol represents an individual mouse. Graph shows mean ± SEM. Data were analyzed 
with student t analysis. (A, B) Data were compiled from 3 individual experimets. (C) Feces from the indicated mice 
were collected before the DSS treatment. Fecal commensal bacteria were isolated and the level of C. XIVa was 
determined by qPCR analysis. Graph shows mean ± SEM. Data were compiled from 2 independent experiments and 
analyzed with Mann-Whitney analysis. **P < 0.01 
 83 
4.2.4 IL-17F.S65L regulates colonic Treg cell levels 
Colonic Tregs differentiation is dependent on signals derived from intestinal microbiota 
[260]. The C. XIVa cluster is a major constituent of the mouse gut microbiome and is known to 
promote Treg accumulation in the colon and thereby maintain gut homeostasis [170]. In particular, 
Il17f-/- mice were reported to have elevated levels of colonic Tregs compared to WT mice, with 
ablation of Tregs in Il17f-/- mice claimed to be responsible for reversing the impact of IL-17F 
deficiency [89]. To evaluate the function of IL-17F.S65L in regulating colonic Treg cells, we 
quantified colonic CD4+Foxp3+ cells in Il17fS65L/S65L mice at day 9 post-DSS treatment. As shown, 
the proportion of CD4+Foxp3+ Treg cells was decreased in DSS-treated Il17fS65L/S65L mice, 
compared to WT mice (Figure 4.3A, B). Thus, loss of colonic Treg cells correlated with 
exacerbated colitis in this setting. Consistent with the C. XIVa colonization results (Figure 4.3C), 
colonic Treg cell levels in Il17f-/- mice are comparable to those in WT mice (Figure 4.4A,C). 
Furthermore, co-housing with Il17fS65L/S65L mice led to a decreased numbers of enteric Treg cells 
in Il17f-/- mice (Figure 4.4B,C). Taken together, these data indicated that colonic Treg cells 
correlate with levels of C. XIVa. Therefore, the IL-17F.S65L mutation affects Treg cell 
frequencies in DSS colitis, which could be mediated by regulating intestinal C. XIVa. 
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Figure 4.4 IL-17F.S65L mutation is associated with a reduced Foxp3+ Treg cell poplulation in colon 
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Il17fS65L/S65L and Il17f-/- mice were cohoused for 2 weeks to normalize the intestinal microbiome. The indicated mice 
were subjected for DSS treatment for 7 days followed by replacecment with normal drinking water for another 2 days. 
Single cell suspenstions were prepared from the colon tissues harveseted at day 9 post treatment, and cells were 
analyzed by flow cytometry. Cells were gated on the CD45+ and CD4+ live poplulation and stained for Foxp3. 
Representative FACS plots for (A) non-cohoused and (B) cohoused mice. (C) representative FACS plots for  compiled 
results from 4 independent experiments showing percentages of Treg cells in the CD45+ and CD4+ live gate. Graph 
shows mean ± SEM. Data were analyzed by Student’s t-test. ***P < 0.001 
4.2.5 Defining signaling activities of IL-17A and IL-17F in DSS colitis  
The above data showed that Il17a-/- and Il17fS65L/S65L mice are both susceptible to DSS 
colitis, whereas Il17f-/- mice develop less severe inflammation in this model. One hypothesis to 
explain this observation is that IL-17F signals through an alternative receptor that is distinct from 
IL-17RA/RC. As outlined in the Introduction section, recent studies indicated that IL-17F has the 
ability to bind to an IL-17RC/RC homodimeric receptor complex, though whether this dimer 
mediates downstream signals remains unproven [23]. Related to this, an IL-17F/IL-17RC axis was 
reported to promote expression of IL-33, based on results that IL-33 expression is upregulated in 
Il17ra-/- murine lung epithelial cells upon IL-17F but not IL-17A activation [22]. To examine a 
potential function of the IL-17F/IL-17RC axis in cultured cells, I created an IL-17RA-deficient 
fibroblast cell line from ear tissue of Il17ra-/- mice. As expected, after treatment with IL-17F, 
expression of Il6 was upregulated in WT, but not Il17ra-/-, fibroblasts (Figure 4.5A). Unlike a 
previous report [22], Il33 was not detectably elevated by qPCR in response to IL-17F in either 
Il17ra-/- or control WT fibroblasts (Figure 4.5A). To determine if IL-17F was able to mediate Il33 
expression in other cell types, I stimulated murine colonic epithelial cells (CMT93) and a murine 
stromal fibroblast cell line (ST2) with IL-17F. As shown, Il33 was not induced by IL-17F in any 
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of the tested cell lines (Figure 4.5B). These data indicated that IL-33 is likely not an IL-17F target 
gene, in contrast to published studies in this regard.  
To determine if there were any other IL-17RA-independent genes induced by IL-17F, 
Il17ra-/- fibroblasts were treated with IL-17F for 8 hours and RNAseq analysis was performed. 
Gene-specific analysis (GSA; Partek flow) on RNAseq data revealed differential expression of 
genes in IL-17F-treated WT fibroblasts and the WT untreated controls. In total, 24 genes were 
found to be elevated by IL-17F in WT fibroblasts (Table 4.1). However, none of these 24 genes 
were evident in Il17ra-/- fibroblasts (Figure 4.5C, Table 4.2), which indicated that IL-17RA is 
required for IL-17F signaling, at least in fibroblasts. It is not surprising that the number of genes 
activated by IL-17F in WT fibroblasts is quite low, since IL-17F is known to be a weak activator 
for signal transduction [20, 86, 122, 152, 159, 228]. Notably, statistically significant differences 
were found in 22 genes between IL-17F activated and the sham control of Il17ra-/- fibroblasts. 
However, all of these genes are not upregulated by IL-17F activation in WT fibroblasts. In 
addition, the expression level of these genes in IL-17F activated Il17ra-/- fibroblasts is considerably 
low, with a LSmean <5 (Table 4.2.6). Thus, the statistical difference is likely attributed to technical 
variance without biological significance. Therefore, in contrast to published results [22], it appears 
that IL-17RC alone is not sufficient to mediate IL-17F signaling in fibroblasts.  
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Figure 4.5 IL-17RA is required for IL-17F signaling 
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(A) Fibroblasts were isolated from ear tissues of Il17ra-/- or WT control mice and developed into cell lines [261]. 
Il17ra-/- cells and WT cells were activated with 200 ng/ml IL-17F for 6 hours. mRNA was extracted from the cells 
and indicated genes were analyzed by qPCR. Graph shows mean ± SEM. (B) The indicated cell lines were activated 
by 200ng/ml IL-17F for 6 hours. Il33 expression was determined by qPCR. Graph shows mean ± SEM. (C) WT and 
IL-17RA deficient ear-derived fibroblast cell lines were treated with 200 ng/ml IL-17F for 8 hours. RNA-Seq was 
performed on mRNA extracted from WT and Il17ra-/- fibroblasts. Differential expression of genes in IL-17F-activated 
WT fibroblasts and WT sham control as well as IL-17F-activated Il17ra-/- fibroblasts and Il17ra-/- fibroblasts sham 
control were analyzed by GSA. Venn diagram shows differentially or overlapping upregulated genes upon IL-17F 
activation in Il17ra-/- fibroblasts and WT fibroblasts. Upregulated genes were defined as P < 0.05, fold change > 1.4, 
and total count > 5. 24 genes were upregulated by IL-17F in WT cells, and 22 genes were upregulated by IL-17F in 
Il17ra-/- fibroblasts. No overlapping genes were found by RNAseq analysis.  
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Table 4.2.1 Genes upregulated by IL-17F in WT fibroblasts 
RNAseq analysis performed on WT fibroblasts upon IL-17F activation. Gene expression was compared between IL-
17F treated cells and sham controls. The listed genes had P < 0.05, fold change > 1.4, and total count > 5. 
 
Gene ID P-value Fold change LSMean (IL-17F) LSMean (Sham)
Cxcl5 1.90E-10 3.44 42.61 12.41
Lcn2 2.52E-10 3.73 14.26 3.82
Il6 7.72E-10 3.20 25.75 8.05
Ccl2 6.39E-09 1.74 91.58 52.53
Nfkbiz 2.09E-08 1.79 106.76 59.78
Ptx3 2.93E-08 1.46 219.86 150.87
U90926 3.53E-07 1.63 16.31 9.97
Cemip 6.21E-07 1.54 28.46 18.47
Ccl7 7.90E-07 1.60 14.36 8.98
Ntn1 8.72E-07 1.53 36.91 24.05
Zc3h12a 1.53E-06 1.55 20.47 13.20
Slc7a2 1.80E-06 1.50 28.88 19.21
Ccn5 2.09E-06 1.60 94.58 59.27
Cebpd 1.48E-05 1.62 31.08 19.15
Lif 2.11E-05 1.56 156.47 100.18
Slc16a2 2.52E-05 1.46 13.79 9.46
Ptgs2 3.64E-05 1.47 1285.61 872.82
Wdyhv1 4.12E-05 1.41 12.21 8.68
Ier3 5.30E-05 1.45 132.31 90.97
Atp2b4 1.47E-04 1.46 6.12 4.19
Cxcl1 9.48E-04 1.42 56.56 39.70
Egr1 1.77E-03 1.44 251.68 174.74
Ksr1 8.31E-03 1.40 4.97 3.55
Gm14308 2.39E-02 1.49 5.12 3.44  
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Table 4.2.2 Genes upregulated by IL-17F in Il17ra-/- fibroblasts 
RNAseq analysis performed on Il17ra-/- fibroblasts upon IL-17F activation. Gene expression was compared between 
IL-17F treated cells and sham control. The listed genes had P < 0.05, fold change > 1.4, and total count > 5. 
 
Gene ID P-value Fold change LSMean (IL-17F) LSMean (Sham)
Gm18180 1.75E-03 1.67 1.61 0.97
Gvin1 2.09E-03 3.18 2.78 0.87
Zfp882 2.80E-03 1.40 3.16 2.26
Gm13394 3.70E-03 1.50 4.05 2.69
Gm6245 4.07E-03 1.48 1.81 1.22
Cd72 4.47E-03 1.51 1.62 1.08
Itgb4 5.54E-03 1.41 1.80 1.27
Gm28635 5.60E-03 1.85 1.74 0.94
Gm49388 5.89E-03 1.96 1.55 0.79
Gm38357 7.35E-03 1.48 2.25 1.52
Hist1h2bq 9.76E-03 2.04 1.39 0.68
Fam83c 1.00E-02 1.45 1.24 0.85
Gm13493 1.33E-02 1.52 1.58 1.04
Gm18646 1.35E-02 1.45 1.52 1.05
Cpt1b 1.38E-02 1.48 1.07 0.72
Gm16421 1.51E-02 1.48 1.10 0.74
Zfp184 1.72E-02 1.43 1.68 1.17
Ccnb2-ps 1.87E-02 1.46 1.14 0.78
AY036118 2.02E-02 2.06 2.68 1.30
Gm29808 2.39E-02 1.47 1.04 0.71
Gm11353 2.77E-02 1.57 1.16 0.74
H19 2.99E-02 1.41 1.18 0.84  
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4.2.6 IL-17F.S65L does not affect the development of AGN 
Although IL-17A and IL-17F playing contrasting biological roles in DSS colitis, Il17a-/- 
and Il17f-/- mice showed similar phenotypes in a murine model of AGN [88], with both strains 
resistant to kidney damage during development of AGN. We predicted that Il17fS65L/S65L mice 
would be resistant to AGN because (i) the IL-17F.S65L mutation appears to be a loss-of-function 
mutation in IL-17F in vitro (Figure 3.1), (ii) mice containing this mutation showed a phenotype 
similar to that of Il17a-/- mice in OPC and DSS colitis. To examine the function of the IL-17F.S65L 
mutation in a setting where both IL-17A and IL-17F have a similar phenotype, we opted to use 
AGN. To that end, Il17fS65L/S65L mice, as well as Il17a-/-, Il17f-/-, and WT control mice, were 
immunized with heterologous anti-GBM antibodies, which initiate autoimmune antibody-
mediated inflammation against the basement membrane of kidney. Blood urea nitrogen (BUN) 
was measured at two weeks post-immunization to assess kidney damage. Consistent with previous 
reports [88], both Il17a-/- mice and Il17f-/- mice showed decreased BUN levels compared to the 
WT control mice (Figure 4.6), suggesting a pathogenic function of both IL-17A and IL-17F in 
AGN. However, surprisingly, Il17fS65L/S65L mice did not phenocopy the Il17a-/- or Il17f-/- mice in 
this model, as the BUN levels in Il17fS65L/S65L mice were comparable to those in WT mice (Figure 
4.6). Thus, the IL-17F.S65L mutation does not prevent the development of AGN, which is 











































Figure 4.6 IL-17F.S65L mutation exhibits a distinct phenotype from loss of either IL-17A or IL-17F 
The indicated mice were subjected to anti-GBM nephritis. Renal dysfunction at Day 14 was assessed by determination 
of the serum BUN level. Each dot represents an individual mouse. Graph shows mean ± SEM. Data were pooled from 
two independent experiments. Data were analyzed by ANOVA. ****P < 0.0001. 
4.3 Discussion 
Biologic drugs that target IL-17A were a major addition to the toolbox of drugs for 
autoimmunity. The initial studies of anti-IL-17A drugs showed that they are remarkably successful 
in treatment for psoriasis [77]. Currently, three monoclonal antibodies that block the IL-17A 
signaling pathway are available for psoriasis and psoriatic arthritis patients [78-80]. All of these 
treatments provide almost complete clearance of plaques in moderate-to-severe psoriasis. 
However, one of the side effects of such treatments is exacerbation of IBD, a major drug-safety 
concern [240]. Clinical trials to evaluate the efficacy of secukinumab in treatment of CD patients 
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had to be halted due to worsening IBD [164, 165]. This contrasts with the efficacy of ustekinumab, 
a neutralizing antibody that targets IL-12 and IL-23 [262] and more recently mirikizumab, which 
targets just IL-23 [263]. 
 Subsequent mechanistic studies to explain the surprising impact on IBD indicated that IL-
17A regulated intestinal epithelial permeability via an IL-23-independent pathway [167]. Notably, 
this finding might have been predicted based on early in vivo studies on murine DSS colitis which 
showed that mice treated with anti-IL-17A neutralizing antibodies, or genetically lacking IL-17A, 
IL-17RA or Act1 (a critical adaptor for IL-17 signaling pathway) all showed exacerbated disease 
during DSS colitis [41, 86, 166-169]. Thus, while the DSS colitis model is not a perfect reflection 
of the pathogenesis of human IBD, findings made from the DSS colitis model have been predictive 
with respect to involvement of the IL-17 pathway. 
As noted above, DSS colitis is one of the few settings where blockade or deficiency of IL-
17A and IL-17F exhibit opposing phenotypes [86, 89]. The clinical implications of this 
phenomenon are important, because pre-treatment with monoclonal antibodies against IL-17F 
mitigated the development of DSS-induced colitis, unlike anti IL-17A antibodies [89]. Therefore, 
blockade of IL-17F, but not IL-17A, may be beneficial for treatment of IBD. To explain this 
observation, Iwakura et al. suggested that the suppressed inflammation in Il17f-/- mice might be 
mediated by increased colonization of intestinal C. XIVa [89]. Here, I similarly found that Il17f-/- 
mice showed better outcomes during DSS colitis, yet the C. XIVa levels were comparable between 
Il17f-/- mice and WT mice, indicating a divergence of these phenomena. Thus, more mechanistic 
studies are clearly required to understand the basis of these observations and ultimately to translate 
these findings into the clinical setting.  
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The IL-17F.S65L mutation was discovered in kindred of patients with CMCD in 
Argentina, who unfortunately have been lost to follow-up [99]. The biological impact of the IL-
17F.S65L mutation was illustrated by in vitro experiments, in which the IL-17F.S65L homodimer 
as well as IL-17A/IL-17F.S65L heterodimer failed to induce expression of Il6 and Cxcl1, the 
signature genes in IL-17RA/RC signaling pathway (Chapter 3) [99]. I further determined the in 
vivo activities of the IL-17F.S65L mutation during OPC as described in chapter 3. Il17fS65L/S65L and 
Il17a-/- mice showed similar susceptibility to C. albicans oral infection, but Il17f-/- and WT mice 
were fully resistant. These data indicated that the IL-17F.S65L mutation can block IL-17RA/RC 
signaling in vivo. Therefore, IL-17F.S65L mice could be a useful tool to determine the biological 
functions of the IL-17RA/RC signaling pathway, and to help elucidate the mechanism by which 
IL-17A and IL-17F play differing roles in various disease contexts.  
To better understand how IL-17F promotes intestinal inflammation, and why IL-17A and 
IL-17F behave oppositely in the DSS colitis model, Il17fS65L/S65L mice were subjected to DSS 
treatment. Consistent with observations in OPC, Il17fS65L/S65L mice showed a similar phenotype to 
Il17a-/- mice, namely increased susceptibility to DSS. However, Il17fS65L/S65L and Il17a-/- mice do 
not appear to share the same mechanism of protection against DSS-induced inflammation. Il17a-/- 
mice showed increased intestinal epithelial permeability during DSS colitis, indicating that IL-
17A might function to promote the repair of intestinal epithelium [167, 169]. In contrast, gut 
epithelial integrity was comparable between Il17fS65L/S65L and WT mice post-DSS treatment. We 
do not know the basis for this, but based on the observation that the IL-17A homodimer is 
functional in patients with the IL-17F.S65L mutation, the remaining IL-17A homodimers in 
Il17fS65L/S65L mice might be sufficient to protect the intestinal epithelium during DSS colitis.  
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C. XIVa, part of the commensal microbiome, has long been known to regulate intestinal 
inflammation by promoting differentiation of Tregs [170]. I found that decreased colonization of 
C. XIVa correlated with decreased colonic Treg levels in Il17fS65L/S65L mice during DSS colitis. 
Cohousing Il17fS65L/S65L and Il17f-/- mice together led to decreased levels of C. XIVa in Il17f-/- mice, 
which could worsen the severity of colitis in Il17f-/- mice. Therefore, the C. XIVa-mediated 
downregulation of Tregs might explain the elevated inflammation following DSS treatment in 
Il17fS65L/S65L mice. Notably, if the IL-17F.S65L mutation modulates C. XIVa level by antimicrobial 
peptides, which have a directly killing effect on bacteria, then we would expect to see increased 
levels of C. XIVa in Il17fS65L/S65L mice when Il17fS65L/S65L and Il17f-/- mice are cohoused. However, 
I observed decreased levels of C. XIVa in Il17f-/- mice after cohousing, indicating that the IL-
17F.S65L mutation indirectly downregulates intestinal colonization of C. XIVa. Further efforts 
will be needed to sort out how this occurs. 
Recently, crystal structure analysis revealed that IL-17F can bind to an IL-17RC 
homodimeric receptor complex [23]. I speculate that this finding may help to explain the 
contrasting phenotypes of Il17a-/- mice and Il17f-/- mice in the context of DSS colitis (Figure 4.7). 
IL-17A may signal through the IL-17RA/RC receptor complex to protect mice from epithelial 
damage, while IL-17F may be signaling through the IL-17RC/RC receptor to promote 
inflammation during DSS colitis (Figure 4.1). The IL-17F.S65L mutation specifically impairs an 
interaction between IL-17F and the IL-17RA subunit. Thus, this single point mutation is likely to 
only block the binding of IL-17F to IL-17RA/RC receptor complex without disturbing the IL-
17F/IL-17RC axis. Regarding the phenotype in the DSS colitis model, we postulate that the IL-
17F.S65L mutation may lack signaling through the IL-17RA/RC complex, while keeping the IL-
17F/IL-17RC axis intact. This could potentially explain why Il17fS65L/S65L mice showed a 
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phenotype similar to that of Il17a-/- mice, even though the IL-17F.S65L mutation is localized on 
IL-17F. Notably, the phenotype of the Il17fS65L/S65L mice is not as strong as that of Il17a-/- mice, 
since most of the Il17a-/- mice needed to be sacrificed before day 8 post-treatment, while 
Il17fS65L/S65L mice survived somewhat longer. Furthermore, impaired gut epithelial integrity has 
been reported in Il17a-/- mice, yet I did not observe this in Il17fS65L/S65L mice. Together, these data 
are consistent with a model in which a functional IL-17A homodimer could partially compensate 
for the loss of IL-17RA/RC signaling in Il17fS65L/S65L mice.  
To further explore the ramifications of the Il17fS65L/S65L mutation, we used an AGN model. 
IL-17A and IL-17F are both reported to be pathogenic in this setting [88]. We confirmed the 
disease-promoting effects of both IL-17A and IL-17F in our hands, but interestingly and 
unexpectedly, the IL17F.S65L mutation did not ameliorate the kidney damage during AGN. This 
intriguing observation could also be explained by the aforementioned IL-17F/IL-17RC hypothesis: 
that is, the IL-17RA/RC heterodimeric receptor complex and the IL-17RC/RC homodimeric 
complex might mediate non-redundant signaling pathways to promote inflammation during AGN. 
The IL-17F.S65L mutation only blocks binding to the IL-17RA/RC receptor, thus leaving the IL-
17F/IL-17RC axis intact. Although IL-17RA/RC-mediated signaling could be impaired by the IL-
17F.S65L mutation, the remaining IL-17A homodimers may be sufficient to induce kidney 
damage via signaling through the IL-17RA/RC heterodimeric receptor. Therefore, the IL-
17F.S65L mutation does not result in decreased inflammation or kidney damage during AGN. 
Based on these in vivo results, I hypothesized that IL-17F could signal through the IL-
17RC/RC homodimeric receptor complex. This hypothesis was tested in cell line-based assays by 
determining the gene activation profile of Il17ra-/- fibroblasts upon IL-17F treatment (Fig 4.5). 
RNAseq analysis revealed that IL-17F failed to induce expression of any IL-17F target genes in 
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an IL-17RA-deficient fibroblast cell line. Although I do see certain genes that are upregulated by 
IL-17F treatment in Il17ra-/- fibroblasts, these genes are not upregulated in WT fibroblasts upon 
IL-17F activation. Additionally, these genes appear to have a low overall expression level. Thus, 
although statistically significant, these differences might not be biologically significant. Taken 
together, these data imply that IL-17RA is required for IL-17F-mediated signaling. There results 
contrast with a report showing that IL-33 may be a target gene downstream of the IL-17F/IL-17RC 
axis in an IL-17RA independent manner [22]. However, I found no evidence of IL-17F-mediated 
IL-33 induction in multiple cell lines. Notably, the expression of IL-17RC varies in different cell 
types and is particularly high in colonic epithelial cells [85]. Thus, signaling through the IL-17RC 
homodimeric receptor complex may be tissue- and cell type-specific. mRNA screening in colonic 
epithelial cells or organoids might provide informative results regarding the IL-17F/IL-17RC axis.  
In summary, Il17fS65L/S65L mice were used to delineate the different biological activities of 
IL-17A and IL-17F in two autoimmune disease models. In the DSS colitis model, Il17a-/- and Il17f-
/- mice were reported to have opposite phenotypes. I showed that Il17fS65L/S65L mice exhibited more 
severe disease during DSS colitis, which is similar to findings in Il17a-/- mice. In an AGN model, 
both IL-17A and IL-17F promote kidney damage. Surprisingly, the kidney damage in Il17fS65L/S65L 
mice is comparable to that in WT mice. The results from both of the in vivo experiments can be 
explained by a hypothesized IL-17F/IL-17RC axis, but this hypothesis was not supported by my 
cell-line based experiments. Thus, further studies are still required to fully understand the 




Figure 4.7 Speculative IL-17RA/RC and IL-17RC axis in DSS colitis model 
IL-17RA/RC axis prevents the DSS induced colitis, whereas IL-17RC axis promotes the DSS induced colitis. Since 
both IL-17A and IL-17A/F are purposed to activate the IL-17RA/RC axis, IL-17F.S65L mutation could partially 
suppress the IL-17RA/RC axis. Therefore, Il17fS65L/S65L mice showed a pathogenic phenotype in DSS colitis model, 
but the gut epithelial integrity is not impaired by IL-17F.S65L mutation. 
 
 99 
5.0 Conclusion and Future directions 
5.1 Summary 
In this dissertation, I took advantage of a naturally occurring mutation, IL-17F.S65L, to 
explore the in vivo biological activities of IL-17A and IL-17F during infection and autoimmune 
disease. In Chapter 3, I found that Il17fS65L/S65L mice were mildly susceptible to OPC, which is 
similar to the susceptibility of Il17a-/- mice to OPC, but strikingly different from that of Il17f-/- 
mice. The increased susceptibility in Il17fS65L/S65L mice might be attributed to impaired expression 
of CXC chemokines and reduced neutrophil recruitment to the oral mucosa. I further found that 
the cellular sources of IL-17F are  T cells, innate TCRαβ+ cells, and potentially ILC3s, which 
are canonical activators for innate type 17 immunity. The activation of innate type 17 immunity 
during OPC could be modulated by commensal microbiome such as SFB but does not require c-
Fos expression in the oral epithelium. These data indicated a protective role of IL-17F during OPC 
and help to reconcile the observations that while IL-17F-deficient mice are fully resistant to OPC, 
a loss-of-function mutation in IL-17F leads to CMCD in humans.  
In Chapter 4, the Il17fS65L/S65L mice were used in two autoimmune disease models, DSS-
induced colitis and AGN.  Il17fS65L/S65L mice shared a similar phenotype with Il17a-/- mice during 
DSS colitis, in which both were susceptible to pathology resulting from DSS treatment. However, 
unlike IL-17A, the IL-17F.S65L mutation does not appear to influence the gut epithelial integrity 
after DSS treatment. Instead, enteric C. XIVa colonization, as well as colonic Tregs, were both 
found to be decreased in Il17fS65L/S65L mice. The decreased C. XIVa colonization might be 
attributed to the increased severity of DSS colitis in Il17fS65L/S65L mice, because cohousing 
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Il17fS65L/S65L and Il17f-/- mice resulted in lower C. XIVa levels and worse disease outcomes in Il17f-
/- mice. In the AGN model, Il17fS65L/S65L and WT mice showed comparable kidney damage, 
surprisingly different from both Il17a-/- and Il17f-/- mice. Therefore, Il17fS65L/S65L mice exhibit a 
Il17a-/--like phenotype in DSS colitis model, but the Il17a-/--like phenotype was surprisingly not 
observed in AGN model.  
5.2 Unifying discussion, outstanding questions and future directions 
Current and previous studies of the IL-17 family of cytokines reveal many similarities 
between IL-17A and IL-17F. Structurally, IL-17A and IL-17F share 56% homology at the amino 
acid sequence level [6]. These two cytokines also adopt a cysteine knot fold as a unique structural 
feature that distinguishes them from other families of cytokines [12]. This distinctive structure 
underlies the binding of IL-17A and IL-17F to the IL-17RA/IL-17RC receptor complex, and these 
cytokines induce quantitatively similar signaling pathways [21]. Thus, IL-17A and IL-17F have 
similar, yet not entirely overlapping, biological functions in vitro.  
Consistent with the in vitro results, IL-17A and IL-17F exhibit similar in vivo biological 
activities in many models, for example AGN. Loss of either IL-17A and IL-17F prevents the 
development of AGN, as Il17a-/- and Il17f-/- mice are equally resistant to this disease [88]. Despite 
the similarities between IL-17A and IL-17F that are seen in structural analysis, and in vitro studies, 
IL-17A and IL-17F still exert distinct in vivo biological activities, which has been demonstrated in 
both infections and autoimmune diseases. In many settings, IL-17A plays a critical role while IL-
17F is less essential. A model of murine OPC is an example of this category; whereas Il17a-/- mice 
exhibit increased susceptibility to OPC compared to WT mice, the antifungal activity of IL-17F 
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can be only detected under IL-17A and IL-17F double blockade condition, which caused an 
elevated susceptibility to OPC over IL-17A single blockade [87]. In a rare second category, IL-
17A and IL-17F exhibit opposite biological activities, namely in the DSS colitis model. IL-17A 
deficiency worsens DSS-induced colitis, but loss of IL-17F leads to a protective phenotype [86, 
89]. Therefore, IL-17A and IL-17F show similar in vivo biological activities in most cases, but still 
behave differently in certain animal models. The mechanism of the different in vivo functions of 
IL-17A and IL-17F is largely unknown.  
To further understand the in vivo biological activities of IL-17F, I developed an IL-
17F.S65L mutant mouse strain. The human IL-17F.S65L mutation has an apparent dominant 
negative effect according to Puel et al., inhibiting signaling of the IL-17AF heterodimer and IL-
17F homodimer when paired with a wild type counterpart in vitro [99]. As noted, the serine residue 
at position 65 of IL-17F is important for the interaction between IL-17F and IL-17RA [19]. Thus, 
replacement of the polar serine with a non-polar leucine impairs the binding of IL-17F to IL-17RA. 
Therefore, IL-17F.S65L mutation could serve as a useful tool to understand the function of IL-
17F.  
In my dissertation, Il17fS65L/S65L mice were evaluated in three mouse models, OPC, DSS 
colitis, and AGN, with some unexpected outcomes. In the OPC model, blocking IL-17A in Il17f-/- 
mice led to an increased fungal burden that was even higher than that of IL-17A singly deficient 
mice [87]. Thus, I expected that treating Il17fS65L/S65L mice with anti-IL-17A neutralizing antibodies 
would cause a higher susceptibility to OPC compared to IL-17A blockade in WT mice; in other 
words, that the Il17fS65L/S65L would be deficient in IL-17A, IL-17F, and IL-17AF signaling in this 
situation. However, surprisingly, IL-17A blockade in Il17fS65L/S65L mice caused only a similar 
fungal susceptibility to mice with an IL-17A deficiency.  
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In the DSS colitis model, IL-17F deficient mice, either by neutralizing antibody or genomic 
deletion, show ameliorated inflammation [86, 89]. In contrast, Il17fS65L/S65L mice show exacerbated 
colitis after DSS treatment, even though these mice contain an IL-17F loss-of-function mutation. 
In the AGN model, Il17a-/- and Il17f-/- mice are equally resistant to kidney damage [88]. Since IL-
17F.S65L mutation is deficient in the ability to signal and leads to an Il17a-/--like phenotype in the 
OPC and DSS colitis models, I predicted that Il17fS65L/S65L mice would be similarly resistant to 
kidney damage in AGN model. However, my data revealed that the IL-17F.S65L mutation does 
not impact the kidney damage at all during AGN. Thus, there is clearly context-specific activity 
of IL-17F, which needs to be defined in greater detail. 
To explain the unexpected results from Il17fS65L/S65L mice, I made two speculations. First, 
based on the crystallographic structural analysis showing that IL-17F can interact with IL-
17RC/RC homodimeric receptor [23], I postulate a model in which that IL-17F can signal through 
an IL-17RC/IL-17RC homodimeric receptor, and the signals mediated by this complex are 
nonredundant to the signals mediated by a heterodimeric IL-17RA/IL-17RC receptor complex. 
Hereafter, I will refer to the IL-17F-mediated IL-17RC/IL-17RC signaling as the IL-17RC axis 
and the more canonical IL-17RA/IL-17RC signaling as the IL-17RA/RC axis. Second, the 
binding site of IL-17F S65 is located at IL-17RA [19]. Therefore, I hypothesize that the IL-
17F.S65L mutation specifically blocks the IL-17RA/RC axis but does not impact the IL-17RC 
axis. All of the unexpected findings in Il17fS65L/S65L mice could be explained by these possibilities, 
as outlined in detail below.  
If the above model is correct, then in murine OPC the IL-17RA/RC axis would be predicted 
to potently clear C. albicans from the oral cavity. The IL-17RC axis may also exert some fungal 
clearance activity but is apparently dispensable when the IL-17RA/RC axis is functional. In 
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support of this, our current and previous studies showed that blocking IL-17F alone does not 
impact the susceptibility of OPC, while inhibiting IL-17F in IL-17A deficient mice can further 
increase the fungal burden upon C. albicans oral infection [87]. In Il17fS65L/S65L mice, the IL-
17RA/RC axis would be impaired by the IL-17F.S65L mutation, but the IL-17RC axis would still 
be intact. Consistent with this model, we found that Il17fS65L/S65L mice have a fungal burden that is 
similar to Il17a-/- mice during OPC. Thus, treating Il17fS65L/S65L mice with anti-IL-17A neutralizing 
antibodies would not be expected to further increase the susceptibility to OPC, as the IL-17RA/RC 
axis is fully blocked by IL-17F.S65L mutation and of course anti-IL-17A neutralizing antibodies 
do not affect the IL-17RC axis. (Figure 5.1) (the mechanism of how IL-17F.S65L could completely 
block IL-17RA/IL-17RC signaling is discussed in detail in Chapter 3.3).  
If these speculations are true, then in the DSS colitis model I propose that the IL-17RA/RC 
axis mediates the protective role of IL-17A, whereas the IL-17RC axis signaling mediates the 
pathogenic activity of IL-17F. Since we posit that the IL-17F.S65L mutation only blocks the IL-
17RA/IL-17RC signaling pathway, it makes sense that Il17fS65L/S65L mice exhibit a qualitatively 
similar phenotype to Il17a-/- mice, rather than to Il17f-/- mice. Notably, Il17a-/- mice were reported 
to have increased intestinal epithelial permeability during DSS colitis [167, 169]. However, I 
showed that the gut epithelial integrity in Il17fS65L/S65L mice was comparable to WT mice post-DSS 
treatment. Although I have not yet probed the mechanism of this difference between Il17a-/- mice 
and Il17fS65L/S65L mice, I hypothesize that the residual IL-17A homodimers in Il17fS65L/S65L mice are 
sufficient to protect the intestinal epithelium during DSS colitis. Therefore, this model could 
reconcile the conflict that Il17f-/-mice are protected from DSS-induced colitis, while mice 
containing a loss-of-function mutation on IL-17F have a pathogenic phenotype (Figure 4.7).  
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The results from Il17fS65L/S65L mice in the AGN model are intriguing, since Il17fS65L/S65L 
mice do not share a similar phenotype with Il17a-/- mice in this model, unlike the OPC and DSS 
colitis models. To explain this unexpected result, I hypothesize that the pathogenic roles of the IL-
17RA/RC axis and IL-17RC axis are mediated by different mechanisms. In this setting, loss of 
either axis would prevent the development of AGN. In other words, Il17a-/- mice are resistant to 
AGN due to loss of the IL-17RA/RC axis, while the phenotype of Il17f-/- mice could be attributed 
to a deficiency of IL-17RC axis. Since I predict that IL-17F.S65L mutation only inhibits the IL-
17RA/RC axis, Il17fS65L/S65L mice are thus different from Il17f-/- mice in AGN. In terms of the IL-
17RA/RC axis, although the IL-17F.S65L mutation blocks this pathway, the remaining IL-17A 
homodimers might be sufficient to compensate for the impact of the IL-17F.S65L mutation. By 
this logic, we can explain why the Il17fS65L/S65L mice do not share a same phenotype with Il17a-/- 
mice during AGN. Taken together, the enigmatic findings from Il17fS65L/S65L mice in the AGN 
model could be explained by the speculative model that I discussed above, though clearly direct 
experimentation is needed to prove this directly (Figure 5.2).  
Notably, in explaining the unexpected phenotypes of Il17fS65L/S65L mice based on these 
speculations, the predicted compensatory effect of the remaining IL-17A homodimers must be 
different among the three animal models. One way to explain these different compensation effects 
could be attributed to the IL-17AF heterodimer, which has been convincingly demonstrated to 
exist but is hard to study due to lack of reagents that can block it while sparing IL-17A and IL-17F 
homodimers. As Puel et al. demonstrated, the IL-17F.S65L mutation blocks the signaling activities 
of both IL-17AF and IL-17F. If IL-17AF is indeed the major activator for the IL-17RA/IL-17RC 
signaling during OPC, then the IL-17F.S65L mutation should fully inhibit the signals mediated by 
IL-17RA/RC axis, as discussed in Chapter 3.3. In contrast, in AGN, the IL-17RA/RC axis might 
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be preferentially activated by the IL-17A homodimer. Therefore, any compensation from the 
remaining IL-17A homodimers could promote kidney damage in Il17fS65L/S65L mice during AGN, 
perhaps explaining what makes Il17fS65L/S65L mice different from Il17a-/- mice in this setting. In the 
case of DSS colitis, both IL-17A and IL-17AF are speculated to be involved in the IL-17RA/RC 
axis. Thus, the remaining IL-17A could only partially compensate for the loss of the IL-17RA/RC 
axis, and thus the Il17fS65L/S65L mice still exhibit a phenotype similar to Il17a-/- mice during DSS 
colitis.  
 
Although the models discussed above could help to explain the unexpected results obtained 
with Il17fS65L/S65L mice, none yet have empirical support. Indeed, my RNAseq analysis on Il17ra-
/- fibroblasts indicated that IL-17RA is required for all IL-17F-induced genes, at least in fibroblasts, 
which make the first model less likely. The second model could be confirmed by biophysical 
approaches, such as isothermal titration calorimetry or crystallographic analysis, which could be 
good experiments for future research. Therefore, the in vivo function of IL-17F clearly requires 
more in-depth focus.  
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Figure 5.1 Speculative IL-17RA/RC and IL-17RC axis in OPC model 
 IL-17RA/RC axis promotes fungal clearance during OPC, while the anti-fungal activity of IL-17RC axis is to a lesser 
extent. Upon C. albicans oral infection, IL-17RA/RC axis is mostly activated via IL-17A/F heterodimer, which could 
be blocked by IL-17F.S65L mutation. Thus, we could find a fully suppressed IL-17RA/RC axis in Il17fS65L/S65L mice 
during OPC, which is similar to Il17a-/- mice.     
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Figure 5.2 Speculative IL-17RA/RC and IL-17RC axis in AGN model 
Both IL-17RA/RC axis and IL-17RC axis promote kidney damage in AGN model. The IL-17RA/RC axis is speculated 
to be only activated by IL-17A homodimer in this model. Therefore, IL-17F.S65L mutation does not impair the IL-
17RA/RC axis, which makes Il17fS65L/S65L mice have a comparable phenotype to WT mice during AGN. 
5.3 Conclusion 
 The work presented in this dissertation has expanded our understanding of the similarities 
and differences between IL-17A and IL-17F, though it has raised many questions as well. To 
understand the in vivo function of IL-17F, I took advantage of the IL-17F.S65L mutation, which 
is a dominant negative mutation that blocks the function of both IL-17F and IL-17AF. I developed 
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a mouse strain with the IL-17F.S65L mutation and used these mice in multiple infectious and 
autoimmune disease models, where IL-17A and IL-17F exert similar or distinct biological 
activities. Surprisingly, Il17fS65L/S65L mice exhibited unexpected phenotypes in all of the animal 
models. As outlined above, a speculative model of the IL-17RC axis can be used to explain these 
unexpected results from Il17fS65L/S65L mice, which could be a platform for future hypothesis testing 
of the functions of the enigmatic IL-17F cytokine. 
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